Mouthpiece, interface, and drug assembly for aerosolized drug administration

Abstract

Provided herein are apparatuses, systems, and methods for administration of an aerosolized drug. The systems can include a holding chamber, a drug assembly, a vaporizer, and a mouthpiece. The holding chamber, drug assembly, vaporizer, and mouthpiece can all include mating mechanisms for interfacing with one another, thereby providing safe, efficient, and airtight connections between the holding chamber, drug assembly, vaporizer, and mouthpiece.

Description

Atty. Docket No. 119186-TBDMOUTHPIECE, INTERFACE, AND DRUG ASSEMBLY FOR AEROSOLIZED DRUG ADMINISTRATIONCROSS-REFERENCE TO RELATED APPLICATIONS[OOOIJThis application claims the benefit of U.S. Application No. 63 / 709,241 , filed October 18, 2024, the entire contents of which are incorporated herein by reference in their entirety.FIELD

[0002] The present disclosure relates generally to mouthpieces, interfaces, drug assemblies, and methods for administration of an aerosolized drug.BACKGROUND

[0003] Inhalation of an aerosolized drug is a technique to deliver drugs to a user. The aerosolized drug is inhaled into the lungs of a patient, which leads to absorption of the drug into the bloodstream and systemic distribution.BRIEF DESCRIPTION OF THE DRAWINGS

[0004] Further features of the present disclosure will become apparent to those skilled in the art to which the present disclosure relates from reading the following specification with reference to the accompanying drawings, in which:

[0005] FIG. 1 illustrates a mouthpiece.

[0006] FIG. 2 illustrates a mouthpiece.

[0007] FIG. 3A illustrates a mouthpiece.

[0008] FIG. 3B illustrates a mouthpiece.

[0009] FIG. 4 illustrates a mouthpiece.

[0010] FIG. 5 illustrates an aerosol containment device.

[0011] FIG. 6A illustrates a mouthpiece and an aerosol containment device.

[0012] FIG. 6B illustrates a mouthpiece and an aerosol containment device.

[0013] FIG. 6C illustrates a mouthpiece and an aerosol containment device.

[0014] FIG. 7A illustrates a mouthpiece and an aerosol containment device.1106261231.6Atty. Docket No. 119186-TBD

[0015] FIG. 7B illustrates internal components of a mouthpiece and an aerosol containment device.

[0016] FIG. 7C illustrates a mouthpiece and an aerosol containment device.

[0017] FIG. 7D illustrates internal components of a mouthpiece and an aerosol containment device.

[0018] FIG. 8A illustrates a valve of a holding chamber lumen in an open state.

[0019] FIG. 8B illustrates a valve of a holding chamber lumen in a closed state.

[0020] FIG. 9 illustrates a drug assembly.

[0021] FIG. 10 illustrates an exploded view of a drug assembly.

[0022] FIG. 11 illustrates a drug assembly and a holding chamber.

[0023] FIG. 12 illustrates a drug assembly coupled to a holding chamber.

[0024] FIG. 13A illustrates internal components of the drug assembly.

[0025] FIG. 13B illustrates internal components of the drug assembly.

[0026] FIG. 13C illustrates a drug assembly.

[0027] FIG. 13D illustrates a drug assembly.

[0028] FIG. 14 illustrates a vaporizer.

[0029] FIG. 15 illustrates the internal components of a holding chamber coupled to a drug assembly coupled to a vaporizer.

[0030] FIG. 16A illustrates a holding chamber and a drug assembly being coupled to a vaporizer.

[0031] FIG. 16B illustrates a drug assembly attachment port of a vaporizer.

[0032] FIG. 17 illustrates a holding chamber and a drug assembly coupled to a vaporizer.

[0033] FIG. 18 illustrates a system for aerosolizing a drug.

[0034] FIG. 19 illustrates a flow chart for a method for engaging a mouthpiece to a holding chamber.

[0035] FIG. 20 illustrates a flow chart for a method for administration of a drug to a patient in need thereof.

[0036] FIG. 21 illustrates a flow chart for a method of forming an aerosolized drug and administering an aerosolized drug to a patient in need thereof.2106261231.6Atty. Docket No. 119186-TBDDETAILED DESCRIPTION

[0037] It will be appreciated that for simplicity and clarity of illustration, where appropriate, reference numerals have been repeated among the different figures to indicate corresponding or analogous elements. In addition, numerous specific details are set forth in order to provide a thorough understanding of the embodiments described herein. However, it will be understood by those of ordinary skill in the art that the embodiments described herein can be practiced without these specific details. In other instances, methods, procedures, and components have not been described in detail so as not to obscure the related relevant feature being described. The drawings are not necessarily to scale and the proportions of certain parts may be exaggerated to better illustrate details and features. The description is not to be considered as limiting the scope of the embodiments described herein.

[0038] Several definitions that apply throughout this disclosure will now be presented.

[0039] The term “coupled” is defined as connected, whether directly or indirectly through intervening components, and is not necessarily limited to physical connections. The connection can be such that the objects are permanently connected or releasably connected. The term “substantially” is defined to be essentially conforming to the particular dimension, shape or other word that substantially modifies, such that the component need not be exact. For example, substantially cylindrical means that the object resembles a cylinder, but can have one or more deviations from a true cylinder. The term “comprising” means “including, but not necessarily limited to”; it specifically indicates open-ended inclusion or membership in a so-described combination, group, series and the like.

[0040] As used herein, when referring to any numerical value, the term “about” means a value falling within a range that is ± 10 percent of the stated value.

[0041] Ranges can be expressed herein as from “about” one particular value, and / or to “about” another particular value. When such a range is expressed, a further aspect includes from the one particular value and / or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms a further aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other3106261231.6Atty. Docket No. 119186-TBD endpoint and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. Where the term “about” is used in relation to a particular value, the term “about” is optional. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11 , 12, 13, and 14 are also disclosed.

[0042] The term “aerosol,” “aerosolized,” or any other variation of such terms, is defined as a substance (e.g., the drug) diffused or suspended in air, or turning a substance (e.g., the drug) into a form that can be diffused or suspended in air.

[0043] As used herein, unless stated otherwise, the term “patient” refers to a subject having at least one of the diseases or disorders as disclosed herein. The subject is typically a human or non-human animal e.g. mammal. Preferably, the subject is a human.

[0044] As used herein, unless stated otherwise, the terms “mental disorder” and “nervous system disorder” mean any disorder that affects mood, thinking and behaviour, including but not limited to, postpartum depression, sleep disturbance, major depressive disorder, persistent depressive disorder, bipolar disorder (such as bipolar I disorder and bipolar II disorder), anxiety disorder, posttraumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorder and psychoactive substance abuse. Diagnosis of a patient with a “mental disorder” or a “nervous system disorder” can be in accordance with the Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5) published by the American Psychiatric Association as suffering from a mental disorder or nervous system disorder. Alternatively, the disorder can be diagnosed in accordance with the International Classification of Diseases 11th Revision (ICD-11), published by the World Health Organisation. As will be understood, diagnostic manuals and disease classification systems such as DSM and ICD may be revised from time to time. The diagnosis can be by a licensed professional in accordance with accepted medical practice. The licensed professional in accordance with accepted medical practice can be, but is not limited to, a physician or a psychologist. It is not sufficient that the human subject themself considers that they are suffering from one of the disorders.4106261231.6Atty. Docket No. 119186-TBD

[0045] As used herein, unless stated otherwise, the terms “treating” and “treatment” include the management and care of a patient for the purpose of combating a disease or disorder and includes administration of drugs (e.g. by the methods and systems disclosed here) according to the present application to alleviate the signs and / or symptoms or eliminate the disease or disorder.

[0046] The present application provides a method for administration for drugs (e.g., 5- Methoxy-N,N-Dimethyltryptamine, tetrahydrocannabinol, etc.) through inhalation into the lungs of an aerosolized drug ultimately leading to the absorption of the drug into the bloodstream and systemic distribution. The aerosolized drug can be generated by exposing drug-containing materials to high temperatures. The drug can be heated to a vapor then subsequently cooled and condensed into an aerosolized drug. The aerosolized drug can be delivered with a volume of air.

[0047] Based on their pharmacological activities, there are potential medical uses of drugs. For example, uses in human clinical trials and uses in an approved medical product for treatment of patients require administration of the drug in high purity.

[0048] The present application provides a drug (e.g., 5-Methoxy-N,N-Dimethyltryptamine, tetrahydrocannabinol, etc.) for use as a medicament wherein the drug is administered to a patient in need thereof by the method disclosed herein.

[0049] The present application provides a drug (e.g., 5-Methoxy-N,N-Dimethyltryptamine, tetrahydrocannabinol, etc.) for use in the treatment of a disease or disorder wherein the treatment comprises administering the drug to a patient in need thereof, wherein the drug is administered by the method disclosed herein.

[0050] The present application provides the use of a drug (e.g., 5-Methoxy-N,N- Dimethyltryptamine, tetrahydrocannabinol, etc.) for the manufacture of a medicament for the treatment of a disease or disorder wherein the treatment comprises administering the drug to a patient in need thereof, wherein the drug is administered by the method disclosed herein.

[0051] The present application provides a drug (e.g., 5-Methoxy-N,N-Dimethyltryptamine, tetrahydrocannabinol, etc.) for use as a medicament wherein the drug is administered to a patient in need thereof by the system disclosed herein.5106261231.6Atty. Docket No. 119186-TBD

[0052] The present application provides a drug (e.g., 5-Methoxy-N,N-Dimethyltryptamine, tetrahydrocannabinol, etc.) for use in the treatment of a disease or disorder wherein the treatment comprises administering the drug to a patient in need thereof, wherein the drug is administered by the system disclosed herein.

[0053] The present application provides the use of a drug (e.g., 5-Methoxy-N,N- Dimethyltryptamine, tetrahydrocannabinol, etc.) for the manufacture of a medicament for the treatment of a disease or disorder wherein the treatment comprises administering the drug to a patient in need thereof, wherein the drug is administered by the system disclosed herein.

[0054] The present application provides a drug (e.g., 5-Methoxy-N,N-Dimethyltryptamine, tetrahydrocannabinol, etc.) for use as a medicament wherein the drug is comprised within the drug assembly as disclosed herein.

[0055] The present application provides a drug (e.g., 5-Methoxy-N,N-Dimethyltryptamine, tetrahydrocannabinol, etc.) for use in the treatment of a disease or disorder wherein the drug is comprised within the drug assembly as disclosed herein.

[0056] The present application provides the use of a drug (e.g., 5-Methoxy-N,N- Dimethyltryptamine, tetrahydrocannabinol, etc.) for the manufacture of a medicament for the treatment of a disease or disorder wherein the drug is comprised within the drug assembly as disclosed herein.

[0057] Examples of diseases or disorders that can be treated by the present disclosure include postpartum depression, sleep disturbance, major depressive disorder, persistent depressive disorder, bipolar disorder, anxiety disorder, posttraumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorder, psychoactive substance abuse, insomnia, sleep apnea, alcohol use disorder, suicidal ideation, psychoactive substance use disorder, opioid abuse. In at least one example, the diseases or disorders that can be treated by the present disclosure include postpartum depression, sleep disturbance, major depressive disorder, persistent depressive disorder, bipolar disorder, anxiety disorder, posttraumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorder, psychoactive substance abuse, insomnia, sleep apnea, suicidal ideation.6106261231.6Atty. Docket No. 119186-TBD

[0058] The present application provides a drug (e.g., 5-Methoxy-N,N-Dimethyltryptamine, tetrahydrocannabinol, etc.) for use in treatment of a mental disorder or a nervous system disorder comprising administering the drug to a patient in need thereof, wherein the drug is administered by the method disclosed herein.

[0059] The present application also provides a drug (e.g., 5-Methoxy-N,N- Dimethyltryptamine, tetrahydrocannabinol, etc.) for use in treatment of a mental disorder or a nervous system disorder wherein the drug is administered by the system disclosed herein.

[0060] The present application also provides a drug (e.g., 5-Methoxy-N,N- Dimethyltryptamine, tetrahydrocannabinol, etc.) for use in treatment of a mental disorder or a nervous system disorder comprising administering the drug to a patient in need thereof, wherein the drug is comprised within the drug assembly disclosed herein.

[0061] Examples of mental disorders or nervous system disorders that can be treated by the present disclosure include postpartum depression, sleep disturbance, major depressive disorder, persistent depressive disorder, bipolar disorder, anxiety disorder, posttraumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorder and psychoactive substance abuse. In a preferred example, the mental disorder or nervous system disorder is major depressive disorder.

[0062] The present application also provides a drug (e.g., 5-Methoxy-N,N- Dimethyltryptamine, tetrahydrocannabinol, etc.) for use in treating a treatment-resistant form of a mental disorder or a nervous system disorder comprising administering the drug to a patient in need thereof, wherein the drug is administered by the method disclosed herein.

[0063] The present application also provides a drug (e.g., 5-Methoxy-N,N- Dimethyltryptamine, tetrahydrocannabinol, etc.) for use in treating a treatment-resistant form of a mental disorder or a nervous system disorder comprising administering the drug to a patient in need thereof, wherein the drug is administered by the system disclosed herein.

[0064] The present application also provides a drug (e.g., 5-Methoxy-N,N- Dimethyltryptamine, tetrahydrocannabinol, etc.) for use in treating a treatment-resistant7106261231.6Atty. Docket No. 119186-TBD form of a mental disorder or a nervous system disorder wherein the drug is comprised within the drug assembly disclosed herein.

[0065] Unless stated otherwise, the drug is administered as an aerosolized drug. Administration of an aerosolized drug to a patient by the methods and systems disclosed herein, or as part of the drug assemblies disclosed herein, leads to absorption of the drug into the bloodstream of the patient and can achieve systemic distribution.

[0066] The problem solved by the disclosed subject matter included finding a solution where the active pharmaceutical ingredient (API), or the drug, is properly administered to a patient in need thereof. The disclosed apparatuses, systems, and methods provide better interfacing between components of aerosolized drug systems and devices. For example, the apparatuses, systems, and methods provided herein allow for safe and effective administration of an aerosol, which can include an aerosolized drug.

[0067] The drug can be pre-packaged for transportation and storage. By retaining the drug in a drug cartridge prior to packaging, transportation, and / or storage, the dosage of the drug and the correct administration of the drug via the drug cartridge is ensured. In an example, the drug cartridge can be retained in or integral to a drug cartridge housing. Together, the drug cartridge and drug cartridge housing can be referred to as a drug assembly. However, the drug assembly should be able to retain the drug without leakage to ensure that the correct dosage of the drug is provided. The drug assembly should also be able to deliver the desired thermal energy to the drug retained thereon so that the drug efficiently vaporizes. Further, the drug assembly can include a fiber pad. The fiber pad should also have sufficient porosity to permit air to flow therethrough to promote the release of the drug.

[0068] In at least one example, the drug cartridge can be retained in a drug cartridge housing during storage, transport and use. When in use, the drug cartridge housing retaining the drug cartridge can be utilized with the vaporizer without the need for removal of the drug cartridge. Retaining the drug cartridge in the housing can, for example, make the cartridge easier to handle and / or, for example, render it more tamper resistant.

[0069] In some examples, the connections between the drug assembly and other components of the aerosolized drug delivery systems should be airtight and create one or more seal(s) such that the aerosolized drug cannot escape the components into8106261231.6Atty. Docket No. 119186-TBD ambient air. If the aerosolized drug escapes to the ambient air, the aerosolized drug can be inhaled by unintended recipients. The interfacing between various components of the system can have feedback mechanisms to ensure that the components are properly connected. For example, the feedback mechanisms can provide audible feedback (e.g., clicking noise), visual feedback, and / or tactile feedback (e.g., vibrations provided by the snap-fit connections of various components) to indicate proper connection of components. When the components are properly connected, the components can create the seal(s) described herein.

[0070] Disclosed herein is a system for administering an aerosolized drug. The system can be operable to provide an aerosolized drug to a patient. The system can include an aerosol containment device, a mouthpiece, a drug assembly, and a vaporizer. The system can be configured to provide airtight connections between components. Further, the system can provide visual, tactile, and / or audible feedback when components are properly coupled. The various components of the system can be coupled to one another in a predefined manner for ease of use. As will be described herein, the various coupling, attachment, and securement features of the components described herein can be configured such that the components are coupled and uncoupled in a predefined order, such that the components can be used as intended, while preventing unintended uses. Due to the system’s ability to produce aerosolized drugs, there are important safety concerns (e.g., bum risks, improper use of drugs, leak prevention, unintended aerosol release, etc.) in using the system. The connections of the components described herein ensure that the system is used as intended.

[0071] FIGS. 1-4 illustrate a mouthpiece 100. In some examples, the mouthpiece 100 can include a body 101 (e.g., all portions of the mouthpiece 100 except for the engagement features) and a plurality of engagement features. The mouthpiece 100 can include one or more engagement features (e.g., mating mechanisms, attachment mechanisms, etc.) extending from the body 101. In some examples, the one or more engagement features can include a first engagement feature 102(a) and a second engagement feature 102(b). The first engagement feature 102(a) and the second engagement feature 102(b) can be configured to releasably couple to corresponding engagement features of a holding9106261231.6Atty. Docket No. 119186-TBD chamber connect portion (e.g., receiving portion). In some examples, the connect portion of the holding chamber can be referred to as a receiving portion of the holding chamber.

[0072] In some examples, the first engagement feature 102(a) can include a locking portion 104(a). The second engagement feature 102(b) can include a locking portion 104(b). In some examples, locking portions 104(a), 104(b) can be tabs. In some examples, locking portions 104(a), 104(b) can be operable to snap (e.g., lock) into place with corresponding projections of the holding chamber. For example, the projections of the holding chamber can fit into receiving portions 106(a), 106(b). When the projections of the holding chamber are locked by locking portions 104(a), 104(b) in the receiving portions 106(a), 106(b) of the mouthpiece 100, rotational displacement of the mouthpiece can be prevented. This rotational displacement can also be referred to as rotational movement herein.

[0073] Coupling the mouthpiece 100 to the holding chamber can require a two-step attachment process, otherwise herein called an installation process. The two-step attachment process can include engaging the mouthpiece to a receiving portion of the holding chamber and rotating the locking portions 104(a), 104(b) along the projections of the holding chamber, thereby locking the locking portions 104(a), 104(b) on distal ends of the projections when the locking portion 104(a), 104(b) extend past the projections. In some examples, the mouthpiece 100 cannot be linearly translated with respect to the holding chamber until the mouthpiece 100 is properly coupled to the holding chamber, thereby preventing premature actuation and / or unintended actuation of the valve described herein. In some examples, linear translation of the mouthpiece 100 with respect to the holding chamber is restricted until the mouthpiece 100 is properly coupled to the holding chamber, thereby preventing premature actuation and / or unintended actuation of the valve described herein.

[0074] The mouthpiece 100 can further include a lumen 108. When the mouthpiece 100 is coupled to the holding chamber, the lumen 108 can be in fluid communication with an interior containment area (e.g., aerosolized drug containment portion) of the holding chamber. The lumen 108 can be configured to provide the aerosolized drug to the patient. The mouthpiece 100 can further include a lip 112. The lip 112 can be configured such that the patient’s mouth contacts the lip 112 when inhaling the aerosolized drug through10106261231.6Atty. Docket No. 119186-TBD the lumen 108 such that loss of aerosol is avoided. For example, the lip 112 can be configured to fit, at least partially, within the patient’s mouth, such that all of the aerosolized drug is inhaled by the patient.

[0075] In some examples, the lip 112 can have a size and shape configured to aid in inhalation of the aerosolized drug. In some examples, the lip 112 can be operable to aid in translation of the mouthpiece 100 (e.g., aid in allowing the user to press the mouthpiece100 inward towards the holding chamber, as described further herein). In some examples, the lip 112 can have a height (e.g., a distance from a proximal end of the lip 112 nearest the body 101 of the mouthpiece 100 to a distal end of the lip 112 furthest from the body 101). In some examples, the height of the lip 112 can be about 1 millimeter (mm) to about 5 mm, about 5 mm to about 10 mm, about 10 mm to about 15 mm, about 15 mm to about 20 mm, about 20 mm to about 25 mm, or about 25 mm to about 30 mm. In some examples, the lip 112 can have a generally oval cross-sectional shape configured to allow ease of contact with a patient’s mouth, as illustrated for example in FIGS. 3A-3B. In some examples, the lip 112 can have an ovoid or ellipsoid shape. In some examples, when the lip 112 has an oval cross-section and / or ovoid or ellipsoid shape, the lip 112 can have a major diameter and a minor diameter. In some examples, the minor diameter can be about 1 mm to about 5 mm, about 5 mm to about 10 mm, about 10 mm to about 15 mm, or about 15 mm to about 20 mm. The major diameter can be about 5 mm to about 10 mm, about 10 mm to about 15 mm, about 15 mm to about 20 mm, about 20 mm to about 25 mm, about 25 mm to about 30 mm, about 30 mm to about 35 mm, about 35 mm to about 40 mm, about 40 mm to about 45 mm, or about 45 mm to about 50 mm. In some examples, the lip 112 can have a minor diameter of about 10 mm and a major diameter of about 30 mm.

[0076] In some examples, the lip 112 can include a tapered surface 103 from the body101 to the distal end of the lip 112. In some examples, the tapered surface 103 can aid in linear translation of the mouthpiece 100 when the patient’s mouth is fit at least partially over the mouthpiece 100. For example, the patient can insert at least a portion of the lip 112 into the patient’s mouth until the lips of the patient contact the tapered surface 103. Once the patient’s lips contact the tapered surface 103, the patient can push inward on the tapered surface 103, thereby providing a force to translate the mouthpiece 100 inward11106261231.6Atty. Docket No. 119186-TBD towards the holding chamber. In some examples, a surface area of the lip 112 can provide sufficient contact with the patient’s mouth to allow for ease of translation of the mouthpiece 100 inward towards the holding chamber and ease of creating a seal to prevent drug escape during inhalation.

[0077] In some examples, the size and shape of the lip 112 is configured such that the entirety of the aerosolized drug is inhaled by the patient (e.g., the size and shape of the lip 112 prevents escape of the aerosolized drug into the environment). In some examples, the size and shape of the lip 112 can aid in comfort and useability. For example, the size and shape of the lip 112 can be configured to easily interface with a patient’s mouth (e.g., a portion of the lip 112 can fit into a patient’s mouth while also allowing the patient to easily press against the mouthpiece 100 to translate the mouthpiece 100 inwards towards the holding chamber). In some examples, the orientation of the mouthpiece 100 when coupled to the holding chamber can indicate to a patient how to hold the holding chamber (e.g., the lip 112 of the mouthpiece can have a major axis aligning with one or more finger grips of the holding chamber). In some examples, the size and shape of the lip 112 can be configured such that a patient can easily form a seal with the mouthpiece 100 (e.g., the patient’s mouth can easily fit around the lip 112 such that a seal is created by the patient’s mouth around the lip 112).

[0078] The mouthpiece 100 can further include one or more atmospheric channels. For example, the mouthpiece 100 can include a plurality of atmospheric channels 110(a), 110(b), 110(c), 110(d). In some examples, the mouthpiece 100 can include four atmospheric channels where two of the four atmospheric channels are on an opposite side of the lumen 108 from another two of the four atmospheric channels. The plurality of atmospheric channels 110(a), 110(b), 110(c), 110(d) can be in communication with ambient air, such that once the aerosolized drug is inhaled from the holding chamber through the lumen 108, the patient can continue inhaling, thereby preventing a hard stop. As used herein, a hard stop means that there is no further air in the holding chamber for a patient to inhale (e.g., all gas in the holding chamber has been evacuated). By allowing the patient to continue to inhale after the aerosolized drug is evacuated from the holding chamber, it can be ensured that the aerosolized drug reaches the patient’s lungs. For example, allowing the patient to continue to inhale after the aerosolized drug is evacuated12106261231.6Atty. Docket No. 119186-TBD from the holding chamber ensures delivery of the aerosolized drug to a deep lung region of the patient to facilitate systemic absorption. As used herein, the deep lung region of the patient is defined as the part of the lungs where gas exchange occurs. The deep lung region consists of respiratory bronchioles, alveolar ducts, and alveoli.

[0079] The mouthpiece 100 can further include an interior projection 114. The interior projection 114 can be configured to contact a linkage arm of the holding chamber. In some examples, the interior projection 114 can be circular and surround the lumen 108. In some examples, the interior projection 114 can annularly surround the lumen 108. In other examples, the interior projection 114 can be any other shape. The interior projection 114 can have a height sufficient to contact the linkage arm only when a force is provided to push the mouthpiece towards the holding chamber. For example, when the mouthpiece 100 is coupled to the holding chamber via the first engagement feature 102(a) and the second engagement feature 102(b) and no force is applied to the mouthpiece 100, the interior projection 114 does not contact the linkage arm of the holding chamber.

[0080] FIG. 5 illustrates a holding chamber 200. In some examples, the holding chamber 200 can be referred to as an aerosol containment device. The holding chamber 200 can include an aerosol containment portion 204 and a receiving portion 202 (e.g. interface portion). The receiving portion 202 can be configured to releasably couple to the mouthpiece 100. The receiving portion 202 can include one or more projections operable to couple to the one or more engagement features of the mouthpiece. The one or more projections can include one or more finger grips. The holding chamber 200 can include a first finger grip 203(a).

[0081] In some examples, as an alternative to, or in conjunction with, the plurality of atmospheric channels 110(a), 110(b), 110(c), 110(d) in the mouthpiece 100, the holding chamber 200 can include atmospheric channels to allow continued inhalation by the patient (e.g., prevent a hard stop). The atmospheric channels of the holding chamber 200 can be in the receiving portion 202 of the holding chamber 200. In some examples, the atmospheric channels of the holding chamber 200 can allow a patient to continue to inhale after all gas in the aerosol containment portion 204 has been evacuated. The atmospheric channels of the holding chamber 200 can be in communication with ambient air to allow13106261231.6Atty. Docket No. 119186-TBD the patient to continue to inhale ambient air when the aerosol containment portion 204 has been completely evacuated.

[0082] FIG. 6A illustrates the holding chamber 200 and the mouthpiece 100. The holding chamber 200 can include a first finger grip 203(a) and a second finger grip 203(b). The holding chamber 200 can include a lumen 208. The lumen 208 can be in communication with the aerosol containment portion 204. The lumen 208 can include a valve having an open state (e.g., activated state or activated position) and a closed state (e.g., inactivated state or inactivated position). In the closed state, the valve can prevent the aerosolized drug from exiting the aerosol containment portion 204 through the lumen 208. In the open state, the valve can allow the aerosolized drug to flow out of the aerosol containment portion 204 through the lumen 208. The holding chamber 200 can further include linkage arm 206. The linkage arm 206 can be configured to actuate the valve to the open state when a force is provided to the linkage arm 206. In some examples, the valve is naturally in a closed state (e.g., normally closed state). For example, when no force is applied, the valve sits in a naturally (e.g., normally) closed state.

[0083] FIGS. 6A-6C illustrate the mouthpiece 100 being connected to the holding chamber 200. The mouthpiece 100 can be oriented such that the first engagement feature 102(a) and the second engagement feature 102(b) are rotationally offset from the first finger grip 203(a) and the second finger grip 203(b), respectively. The mouthpiece 100 can then be engaged to the holding chamber 200. For example, the lumen 108 of the mouthpiece 100 can be aligned with the lumen 208 of the holding chamber 200. The mouthpiece 100 can be inserted until the mouthpiece 100 contacts an interior portion of the holding chamber 200. When the mouthpiece 100 contacts the interior portion of the holding chamber 200, the lumen 108 and the lumen 208 can be fluidically sealed (e.g., the lumen 108 of the mouthpiece 100 forms a friction fit within the lumen 208 of the holding chamber 200).

[0084] As illustrated in FIG. 6B, the mouthpiece 100 can be rotated until the locking portion 104(a) of the first engagement feature 102(a) extends past the first finger grip 203(a) and the locking portion 104(b) of the second engagement feature 102(b) extends past the second finger grip 203(b). When the locking portions 104(a), 104(b) extend past the first finger grip 203(a) and the second finger grip 203(b), respectively, feedback can14106261231.6Atty. Docket No. 119186-TBD be provided. For example, the feedback can include audible feedback (e.g., an audible click). The feedback can include tactile feedback (e.g., a vibration caused by the locking portions 104(a), 104(b) snapping into place). Before the mouthpiece 100 is rotated, the first engagement feature 102(a) and the second engagement feature 102(b) contact an edge 215 of the receiving portion 202 of the holding chamber 200. The contact between the edge 215 and the first engagement feature 102(a) and the second engagement feature 102(b) prevents (e.g., restricts) further linear translation of the mouthpiece 100 with respect to the holding chamber 200. In this manner, actuation of a valve, via a linkage arm 206, in the holding chamber, as described further herein, is prevented.

[0085] FIG. 6C illustrates the mouthpiece 100 fully connected to the holding chamber 200. The first finger grip 203(a) can be locked into place within the gap 106(a) of the first engagement feature 102(a). The second finger grip 203(b) can be locked into place within the gap 106(b) of the second engagement feature 102(b). In this manner, the mouthpiece is prevented from rotating with respect to the holding chamber 200. The mouthpiece 100 can be operable to translate towards the holding chamber 200 when the mouthpiece 100 is coupled to the holding chamber 200. In some examples, translating the mouthpiece 100 towards the holding chamber 200 causes the projection 114 to provide a force to the linkage arm 206. When the linkage arm 206 is provided a sufficient force by the projection 114, the valve can be actuated to the open state and the aerosolized drug can be expelled from the aerosol containment portion. The force can be provided by a patient pressing against the mouthpiece 100 (e.g., against lip 112 with their mouth).

[0086] The installation of the mouthpiece 100 to the holding chamber 200 is a two-step attachment process. First, the mouthpiece 100 is engaged with the receiving portion 202 of the holding chamber 200. For example, engaged with or engaging with or engaging can mean the mouthpiece 100 is fitted to, fitted into, placed in contact with or partially inserted into the receiving portion 202 of the holding chamber. In some examples, engaging the mouthpiece 100 to the receiving portion 202 includes aligning the lumen 108 of the mouthpiece 100 with the lumen 208 of the holding chamber 200 and contacting the lumen 108 of the mouthpiece 100 with the lumen 208 of the holding chamber 200. At this first step, further translation of the mouthpiece 100 towards the holding chamber 200 is prevented (e.g., restricted), which prevents actuation of the valve via the linkage arm15106261231.6Atty. Docket No. 119186-TBD206. At this first step, it is ensured that premature evacuation of the aerosolized drug in the aerosol containment portion is prevented. Second, the first engagement feature 102(a) and the second engagement feature 102(b) are rotated along, for example, over the first finger grip 203(a) and the second finger grip 203(b) until the locking portions 104(a), 104(b) extend past the first finger grip 203(a) and the second finger grip 203(b). Once the locking portions 104(a), 104(b) extend past the first finger grip 203(a) and the second finger grip 203(b), the mouthpiece 100 can be linearly translated towards the holding chamber 200. This linear translation is also referred to as linear displacement or linear motion herein. In some examples, only once the locking portions 104(a), 104(b) extend past the first finger grip 203(a) and the second finger grip 203(b) can the mouthpiece 100 be linearly translated towards the holding chamber 200. Following the rotation of the locking portions 104(a), 104(b) over and past the first finger grip 203(a) and the second finger grip 203(b), the mouthpiece 100 is considered to be in an installed state (also referred to as an installed configuration herein) (e.g., the mouthpiece 100 is ready for use), and the mouthpiece 100 can be subsequently linearly translated towards the holding chamber 200. A user presses on the mouthpiece 100, which then is linearly translated toward the holding chamber 200, to allow for inhalation of the contents. When the mouthpiece 100 is linearly translated towards the holding chamber 200, the projection 114 provides a force to the linkage arm 206, thereby causing a valve to be placed in an open state and allowing inhalation of the contents (e.g., aerosolized drug) within the aerosol containment portion 204. When the mouthpiece 100 is linearly translated towards the holding chamber 200, thereby causing a valve to be placed in an open state and allowing inhalation of the contents (e.g., aerosolized drug) within the aerosol containment portion 204, this may be referred to as an activated position of the mouthpiece.

[0087] In some examples, once the locking portions 104(a), 104(b) extend past the first finger grip 203(a) and the second finger grip 203(b), the mouthpiece 100 can be difficult to remove from the holding chamber 200. For example, a user may need to pull both locking portions 104(a), 104(b) outward to disengage the locking portions 104(a), 104(b) from the first finger grip 203(a) and the second finger grip 203(b). A user may then rotate the mouthpiece 100 such that the locking portions 104(a), 104(b) are no longer in contact with the first finger grip 203(a) and the second finger grip 203(b). By making the16106261231.6Atty. Docket No. 119186-TBD mouthpiece 100 difficult to remove from the holding chamber 200, accidental removal of the mouthpiece 100 can be reduced and / or prevented. In some examples, making the mouthpiece 100 difficult to remove from the holding chamber 200 also prevents confusion over whether a holding chamber 200 has been used. For example, a holding chamber 200 with a mouthpiece 100 attached can be indicative of a previously used holding chamber 200. In this manner, use of a contaminated holding chamber 200 and / or mouthpiece 100 can be reduced and / or prevented. In some examples, making the mouthpiece 100 difficult to remove can reduce the likelihood of a contaminated mouthpiece 100 (e.g., previously used mouthpiece 100) from being reused in a new holding chamber 200 (e.g., since the mouthpiece 100 is difficult to remove, it is less likely that a used mouthpiece 100 would incidentally become uncoupled from a holding chamber 200 such that a user would not know whether the mouthpiece 100 has been previously used).

[0088] The linear motion of the mouthpiece 100 when it is installed over the receiving portion 202 is provided by the configuration of the mouthpiece 100 and the receiving portion 202. Portions of the first engagement feature 102(a) and the second engagement feature 102(b) can be configured to translate along slots (e.g., slots 217(a), 217(b)) in the receiving portion 202. The remaining portions of the first engagement feature 102(a) and the second engagement feature 102(b) can slide along the exterior surface of the first finger grip 203(a) and the second finger grip 203(b), which are contained within the gaps 106(a), 106(b). In this manner, proper installation of the mouthpiece 100 to the receiving portion 202 is required before the mouthpiece 100 can be translated towards the holding chamber 200. The two-step process ensures that the premature and / or unintended evacuation of aerosolized drug (e.g., via premature actuation of the valve in communication with the linkage arm 206) is prevented.

[0089] The mouthpiece 100 and / or the holding chamber 200 can further include one or more markings to mitigate the risk of accidental valve actuation during installation of the mouthpiece 100 to the receiving portion 202 of the holding chamber 200. The one or more visual markings can include projections, indents, or colored markings. For example, the mouthpiece 100 and / or the holding chamber 200 can include one or more visual markings to indicate proper installation of the mouthpiece 100 into the holding chamber 200. For17106261231.6Atty. Docket No. 119186-TBD example, an exterior surface of the receiving portion 202 can include one or more markings, such as a stop line or other marking, indicative of how far to translate the mouthpiece 100 into the holding chamber 200. The stop line can be a marked line of the receiving portion 202. The stop line can indicate to a user when to stop translating the mouthpiece 100 into the holding chamber 200 (e.g., when the distal surface of the mouthpiece 100 reaches the stop line, the user should stop translating the mouthpiece 100 towards the holding chamber 200). The mouthpiece 100 can also include one or more markings to indicate proper insertion of the mouthpiece 100 into the holding chamber 200. For example, the mouthpiece 100 can include visual markings such as stop lines or other markings to indicate how far to insert the mouthpiece 100 into the holding chamber 200 during installation and / or when to begin rotation of the mouthpiece 100.

[0090] In some examples, the mouthpiece 100 may be attached to the holding chamber 200 via linear action. For example, a force can be applied to the mouthpiece 100 to connect the mouthpiece 100 to the holding chamber 200. In some examples, the force required for the initial linear action (e.g., to engage the mouthpiece 100 to the holding chamber 200) can be significantly reduced from the force required for activation of the valve. In this manner, accidental or premature or unintended actuation of the valve in the holding chamber can be prevented since the initial force is significantly reduced from the required force to actuate the valve.

[0091] In some examples, the receiving portion 202 can include a removeable tab or pin. The removeable tab or pin can be located within the receiving portion 202 such that linear translation of the mouthpiece 100 towards the holding chamber 200 is prevented at a stop point. Once the mouthpiece 100 is properly coupled to the holding chamber 200 (e.g., via the two-step attachment process described herein), a user can remove the removeable tab or pin from the receiving portion 202. Once the removeable tab or pin is removed from the receiving portion 202, the mouthpiece 100 can be translated towards the holding chamber 200 to actuate the valve described herein.

[0092] FIGS. 7A-7B illustrate the flow path of the aerosolized drug to the patient when a force is provided to the mouthpiece 100. When the force is provided to the mouthpiece 100 (e.g., via the lip 112), the linkage arm 206 actuates the valve to the open state,18106261231.6Atty. Docket No. 119186-TBD thereby allowing the aerosolized drug to flow as illustrated by arrow 210 along the lumen 108 and out of the mouthpiece 100 to the patient.

[0093] FIGS. 7C-7D illustrate the function of the plurality of atmospheric channels 110(a), 110(b), 110(c), 110(d). Once the aerosolized drug is inhaled by the patient through the mouthpiece 100, ambient air can be drawn through the plurality of atmospheric channels 110(a), 110(b), 110(c), 110(d) along flow paths 212(a), 212(b), 212(c), 212(d) each corresponding to one of the plurality of atmospheric channels 110(a), 110(b), 110(c), 110(d). In this manner, a hard stop (e.g., no airto inhale) is prevented, allowing the patient to continue to inhale after the aerosol containment portion 204 of the holding chamber 200 has been evacuated (e.g., the aerosolized drug has been removed from the aerosol containment portion 204). The plurality of atmospheric channels 110(a), 110(b), 110(c), 110(d) can facilitate continued inhalation after the aerosolized drug is evacuated, thereby facilitating delivery and / or entrance of the aerosolized drug to the patient’s deep lung region e.g. respiratory bronchioles, alveolar ducts and / or alveoli. In some examples, as the aerosolized drug is inhaled, the aerosol containment portion 204 collapses (e.g., the aerosol containment portion 204 can be flexible such that it collapses as air and the aerosolized drug are evacuated).

[0094] As illustrated in FIGS. 7B, 7D, and 8A, when the force is applied to the mouthpiece 100, the linkage arm 206 is contacted causing a valve to actuate to an open state, thereby opening a fluidic channel within lumen 208 and lumen 108. In some examples, the linkage arm 206 is configured to linearly translate within the holding chamber 200. The linkage arm 206 can be mechanically connected to a spring. When the linkage arm 206 is translated toward the aerosol containment portion 204, the linkage arm 206 can overcome the spring force. The linkage arm 206 can cause a valve arm pivot to translate downwards, thereby swinging a valve arm from a horizontal to a vertical position and unsealing a valve from the lumen 208.

[0095] FIG. 8A illustrates the internal components of the holding chamber 200 when the holding chamber 200 is operable to expel (or receive) the aerosolized drug. The linkage arm 206 can be coupled to a valve 214. When a force is provided to the linkage arm 206, the linkage arm 206 can cause the valve 214 to actuate to the open state. For example, actuating the valve to the open state can mean that the valve 214 unseals (e.g., moves19106261231.6Atty. Docket No. 119186-TBD away from) the lumen 208 of the holding chamber 200, thereby allowing fluid communication between the aerosol containment portion 204 and the lumen 208. In this manner, the aerosolized drug can be inhaled out of the aerosol containment portion 204 of the holding chamber 200 (e.g., through the lumen 108 of the mouthpiece 100). Actuating the valve 214 to the open state, unsealing the lumen 208 of the holding chamber 200 can be referred to as opening the lumen 208. In some examples, when the valve 214 is actuated to the open state, the aerosolized drug can be loaded into the aerosol containment portion 204 of the holding chamber 200.

[0096] In some examples, when the mouthpiece 100 is translated towards the holding chamber 200 (e.g., by the patient pressing on the mouthpiece 100 or by the mouthpiece 100 being translated or compressed towards the receiving portion 202), the projection 114 provides a force to the linkage arm 206. The force from the projection 114 can cause the linkage arm 206 to translate towards (e.g., further inward) the aerosol containment portion 204. When the linkage arm 206 translates further into the aerosol containment portion 204, a circular portion 207 of a valve assembly is translated within a slot 211. When the circular portion 207 is translated downward in the slot 211 , the valve arm 209 swings to a vertical position, thereby actuating the valve 214 to an open position. In the open position, the lumen 208 of the holding chamber 200 is placed in fluidic communication with the lumen 108 of the mouthpiece 100.

[0097] FIG. 8B illustrates the internal components of the holding chamber 200 when the holding chamber 200 is not operable to expel (or receive) the aerosolized drug. When the linkage arm 206 is not provided a force, the valve 214 can be in its natural state (e.g., closed state). In the closed state, the valve 214 prevents fluid communication between the aerosol containment portion 204 and the lumen 208. In the closed state, the valve 214 seals the aerosol containment portion 204 from the exterior environment. In this manner, the aerosolized drug can remain in the aerosol containment portion 204 and / or external fluids can be prevented from entering the aerosol containment portion 204. In the closed state, the lumen 208 of the holding chamber 200 is sealed by the valve 214.

[0098] In some examples, when no force is provided to the linkage arm 206, the circular portion 207 is located at an upper position within the slot 211 , as illustrated in FIG. 8B. In the upper position, the valve arm 209 is horizontally oriented (e.g., perpendicular) to the20106261231.6Atty. Docket No. 119186-TBD linkage arm 206. When the valve arm 209 is in the horizontal position, the valve 214 seals the lumen 208, thereby preventing fluid communication between the aerosol containment portion 204 and the lumen 208.

[0099] Other valve configurations can be used as alternatives to, or in conjunction with, the valve assembly described above. For example, the valve 214 can be coupled to a transition mechanism operable to transition the valve 214 between the open state and the closed state. The transition mechanism can be operable to naturally bias the valve 214 to the closed state. The transition mechanism can be operable to actuate the valve to the open state when the force (e.g., from linear translation of the mouthpiece 100 inward) is applied to the transition mechanism. The transition mechanism can include a stored energy mechanism. For example, the transition mechanism may include one or more springs and a horizontal translation mechanism. The horizontal translation mechanism can be operable to transition the valve 214 to the open state when the force is applied to the mouthpiece (e.g., by horizontally translating the valve 214 out of the lumen 208). The horizontal transition mechanism can bias the valve 214 back to the closed state, such that when the force is removed from the mouthpiece 100 (e.g. when the patient discontinues pressing on the mouthpiece), the valve 214 translates back to the closed state. Other types of transition mechanisms can be used to transition the valve 214 from a natural closed state to an open state (e.g., when the force is applied to the mouthpiece 100).

[0100] Other valve configurations for the valve 214 can include ball valves, duckbill valves, slit valves, bite valves, and / or pinch valves. In some examples, the valve 214 can be actuated via a button located on the receiving portion 202 of the holding chamber 200. In some examples, instead of the valve 214, valve free approaches can be implemented with the holding chamber 200. For example, valve free approaches can include pressure differential approaches defined by orifices in the holding chamber 200.

[0101] In some examples, the holding chamber 200 can include one or more indicators. The one or more indicators can be operable to provide an indication that the aerosolized drug has been completely evacuated from the holding chamber 200 (e.g., the aerosolized drug is completely evacuated from the aerosol containment portion 204). For example, the holding chamber 200, in particular aerosol containment portion 204, can include a21106261231.6Atty. Docket No. 119186-TBD window 201 . The window 201 can be a transparent section of the holding chamber 200. The window 201 can allow a user to view the aerosolized drug within the holding chamber 200 and visually determine when the aerosolized drug is completely evacuated from the holding chamber 200. In some examples, the holding chamber 200, in particular the aerosol containment portion 204, can collapse when the aerosolized drug is evacuated, thereby providing a visual indication that the aerosolized drug is completely evacuated from the holding chamber 200. In some examples, the one or more indicators can include specific configurations of the aerosol containment portion 204 when collapsed. For example, the window 201 may include a visual indicator (e.g., marking) which only becomes visible when the aerosol containment portion 204 is collapsed.

[0102] In some examples, a user can provide palpations to the holding chamber 200, in particular the aerosol containment portion 204. If there is no pressure in the holding chamber 200, in particular the aerosol containment portion 204, as detected by the palpations, the user can determine that there is no remaining aerosolized drug in the holding chamber 200, in particular the aerosol containment portion 204. In some examples, other visual indicators can be used to determine that the holding chamber 200, in particular the aerosol containment portion 204, is completely evacuated of the aerosolized drug. For example, sliders, meters, or other mechanical means for determining pressure within the holding chamber 200, in particular the aerosol containment portion 204, can be used to determine whether the aerosolized drug is completely evacuated from the holding chamber 200, in particular the aerosol containment portion 204.

[0103] In some examples, electronic and / or mechanical means can be used to provide visual, audible, and / or tactile feedback to a user that the aerosolized drug has been completely evacuated from the aerosol containment portion 204 of the holding chamber 200. For example, pressure and / or flow based measurements can be used to indicate when the aerosol containment portion 204 has been completely evacuated. In some examples, pressure measurements can be taken by one or more pressure sensors in communication with the aerosol containment portion 204. In some examples, flow measurements can be taken by one or more flow sensors in communication with the aerosol containment portion 204. In some examples, when the pressure measurement22106261231.6Atty. Docket No. 119186-TBD reaches a threshold (e.g., minimal or no pressure left in the aerosol containment portion 204), an indication can be provided to a user. In some examples, when the flow measurement reaches a threshold (e.g., sufficient flow for a period of time indicative that a total volume of gas in the aerosol containment portion 204 has been evacuated) an indication can be provided to a user. In some examples, the indication can be provided by an optical signal (e.g., illuminated LED), a visual indicator (e.g., slider or gauge-based indicator), an audible indicator (e.g., audible click or whistle), and / or a tactile indicator (e.g., vibration provided by a vibration mechanism in the holding chamber 200). In some examples, a controller (e.g., processor) can be included to analyze the measurements and / or cause the indicator to provide the signal of complete evacuation of the aerosol containment portion 204. In some examples, the indicator can be activated when the valve is closed (e.g., after the force has been removed from the mouthpiece 100). In some examples, any indicator described herein can be used in combination with any other indicator.

[0104] FIGS. 9-13D illustrate a drug assembly 300. The drug assembly can be operable to contain a drug. The drug can be heated by the vaporizer described herein. The drug assembly 300 can include a housing 302. The housing 302 can include at least one mating mechanism. In some examples, the at least one mating mechanism can include one or more openings. The one or more openings can include a first opening 304(a) and a second opening 304(b). In some examples, the at least one mating mechanism can include one or more finger grips. For example, the one or more finger grips can include two or more attachment features. The two or more attachment features can be tabs 308(a) and 308(b). The one or more finger grips can include a first drug assembly finger grip 306(a) and a second drug assembly finger grip 306(b). The first drug assembly finger grip 306(a) can be in mechanical communication with tab body 307(a). The tab body 307(a) can include a tab 308(a). The second drug assembly finger grip 306(b) can be in mechanical communication with a tab body 307(b). The tab body 307(b) can include a tab 308(b). The first drug assembly finger grip 306(a) and second drug assembly finger grip 306(b) can be operable to be squeezed (e.g., compressed inwards towards a center of the drug assembly 300), thereby translating the tab bodies 307(a), 307(b) and tabs23106261231.6Atty. Docket No. 119186-TBD308(a), 308(b) outward. In some examples, the drug assembly 300 can include (e.g., contain or house) a drug.

[0105] In some examples, the housing 302 can be heat resistant. For example, the housing 302 can include heat resistant materials. In some examples, the heat resistant materials can include polyetherimide. Polyetherimide can have a heat deflection point of around 200 degrees Celsius. In some examples, the first drug assembly finger grip 306(a) and the second drug assembly finger grip 306(b) can be positioned such that the first drug assembly finger grip 306(a) and the second drug assembly finger grip 306(b) are positioned away from the vaporizer, such that the first drug assembly finger grip 306(a) and the second drug assembly finger grip 306(b) receive limited heat from the vaporizer. By including heat resistant materials and positioning the first drug assembly finger grip 306(a) and the second drug assembly finger grip 306(b) away from the vaporizer, the first drug assembly finger grip 306(a) and the second drug assembly finger grip 306(b) reduce and / or prevent any bum risk to a user when removing the drug assembly 300 from the vaporizer.

[0106] The housing 302 can further include a chimney channel 310. The housing can further include posts 326(a), 326(b). The posts 326(a), 326(b) can be configured to contact the linkage arm 206 when the drug assembly is coupled to the holding chamber 200.

[0107] FIG. 10 illustrates the drug assembly 300 in an exploded view. The drug assembly 300 can include a drug cartridge 312. The drug cartridge 312 can include a chimney 314, a fiber pad 316, and a cartridge base 318. The chimney 314 can couple to the chimney channel 310 via one or more mating mechanisms (e.g., snap fit, friction fit, screws, latches, etc.). An o-ring 322 can be placed between the chimney 314 and the chimney channel 310. The o-ring 322 can provide an additional seal (e.g., friction fit) between the chimney 314 and the chimney channel 310. The fiber pad 316 can be operable to hold the drug to be aerosolized in solid form. The cartridge base 318 can support (e.g., hold) the fiber pad 316. In some examples, the chimney 314 can be press fit into the cartridge base 318 to ensure that all air flow is passed through the fiber pad 316 and the aerosolized drug is generated directly into the holding chamber 200 without drug loss. For example, the press fit between the chimney 314 and the cartridge base 318 can24106261231.6Atty. Docket No. 119186-TBD provide an airtight seal such that no air escapes the connection of the chimney 314 and the cartridge base 318. The drug assembly 300 can further include a safety cover 320. The safety cover 320 can be releasably coupled to the housing 302.

[0108] The fiber pad 316 can be operable to hold a drug in solid form. In some examples, the drug can be 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT), cannabinoid tetrahydrocannabinol, entactogen 3,4-methylenedioxymethamphetamine, ketamine, lysergic acid diethylamide, psilocybin, N,N-dimethyltryptamine, mescaline, other phenylalkylamines, other tryptamines, other ergolines, other serotonergic compounds, second generation psychedelics, nicotine, pentamidine, and / or opioids such as fentanyl, morphine, naloxone, or other drugs configured to be administered in a aerosolized form. In one example, the drug can be 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT), (i.e. , mebufotenin) or pharmaceutically acceptable salts thereof. In some examples, the drug can be hydrophilic or hydrophobic. In some examples, the aerosolization process can differ depending on whether the drug is hydrophilic or hydrophobic. In an example, the drug can have a melting point of about 50 degrees C to about 80 degrees C. In another example, the drug can have a melting point of about 67.5 degrees C. In other examples, other drugs having other melting points can be used. For example, the drug can be an HBr salt of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT), (i.e., mebufotenin) having a melting point of about 173 degrees C. In particular, the drug can be 5-Methoxy-N,N- Dimethyltryptamine (5-MeO-DMT), (i.e., mebufotenin) free base. Preferably, the drug is 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT), (i.e., mebufotenin) free base having a melting point of about 67.5 degrees C. Other drugs having other melting points can be used. In another example, other pharmaceutical salts can be used having melting points of about 100 degrees C to about 250 degrees C. The dose of the drug can be about 0.5 mg to about 100 mg. In some examples, the dose of the drug can be about 1 milligram (mg) to about 25 mg. In some examples, the drug can be pre-metered to specific dose ranges for ease of use in a clinical setting.

[0109] In some examples, the safety cover 320 can have one or more tabs operable to releasably couple to the at least one mating mechanism of the housing 302. In some examples, the one or more tabs on the safety cover can include tabs 324(a), 324(b), 324(c), 324(d). The tabs 324(a), 324(b) can be configured to releasably couple to second25106261231.6Atty. Docket No. 119186-TBD opening 304(b). The tabs 324(c), 324(d) can be configured to releasably couple to first opening 304(b). In some examples, the safety cover 320 can be coupled to the housing 302 before the drug is loaded (e.g., filled) into the drug cartridge 312 (e.g., on the fiber pad 316).

[0110] In some examples, the at least one mating mechanism of the housing 302 can be configured to releasably couple with at least one corresponding mating mechanism of the holding chamber 200. For example, as illustrated in FIG. 11 , the first opening 304(a) can be configured to releasably couple with a tab 205(a) of the first finger grip 203(a). The second opening 304(b) can be configured to releasably couple with a tab 205(b) of the second finger grip 203(b). For example, the first opening 304(a) and the second opening 304(b) can have ledges for receiving the tabs 205(a), 205(b). When the tabs 205(a), 205(b) are moved towards the first opening 304(a) and second opening 304(b), the tabs 205(a), 205(b) can contact the tabs 324(a), 324(b), 324(c), 324(d) of the safety cover 320. The tabs 205(a), 205(b) can provide a force to tabs 324(a), 324(b), 324(c), 324(d), thereby uncoupling the tabs 324(a), 324(b), 324(c), 324(d) from the first opening 304(a) and the second opening 304(b) and releasing the safety cover 320 from the housing 302, as illustrated in FIG. 12. The tabs 205(a), 205(b) can snap on to the first opening 304(a) and second opening 304(b), thereby releasably coupling the drug assembly 300 to the holding chamber 200. In some examples, the safety cover 320 can only be released (e.g., detached, removed or uncoupled) from the housing 302 when the holding chamber 200 is attached to the housing 302. Arrow 301 illustrates the safety cover 320 being released from the housing 302 when the holding chamber 200 is coupled to the housing 302. In some examples, tactile feedback can be provided on the first finger grip 203(a) and the second finger grip 203(b) of the holding chamber 200 when the tabs 205(a), 205(b) are snapped into the first opening 304(a) and the second opening 304(b). The tactile feedback can indicate to the user that the holding chamber 200 has been properly attached to the drug assembly 300. In some examples, when the tabs 205(a), 205(b) snap into the first opening 304(a) and the second opening 304(b), audible feedback can be provided (e.g., a snap sound). The audible feedback can indicate to the user that the holding chamber 200 is properly coupled to the drug assembly 300. In some examples,26106261231.6Atty. Docket No. 119186-TBD the detachment of the safety cover 320 provides a visual indication that the holding chamber 200 is properly attached to the drug assembly 300.

[0111] The safety cover 320 can include other means of attachment to the housing 302. For example, the safety cover 320 may friction fit to the housing 302. For example, the safety cover 320 may be friction fit to the housing 302 such that a force must be applied to the holding chamber 200 to overcome the friction fit and thereby uncouple the safety cover from the housing 302. For example, instead of, or in conjunction with, tabs 324(a), 324(b), 324(c), 324(d), the safety cover 320 may include a semi-rigid material which forms a friction fit with the first opening 304(a) and the second opening 304(b), such that the holding chamber 200 must be forced downward into the first opening 304(a) and the second opening 304(b) to uncouple the safety cover 320. In some examples, the safety cover 320 can include a semi-rigid material which forms a friction fit with the first drug assembly finger grip 306(a) and the second drug assembly finger grip 306(b), such that the holding chamber 200 must be forced downward into the first opening 304(a) and the second opening 304(b) to uncouple the safety cover 320. The safety cover 320 can include projections which engage with an interior wall of the first opening 304(a) and the second opening 304(b). The projections can be operable to retain the safety cover 320 to the housing 302 until the holding chamber 200 is coupled to the housing 302. For example, when the first finger grip 203(a) and the second finger grip 203(b) are inserted into the first opening 304(a) and the second opening 304(b), the first finger grip 203(a) and the second finger grip 203(b) can contact the safety cover 320 and provide a sufficient force to push the projections of the safety cover 320 out of the first opening 304(a) and the second opening 304(b), thereby uncoupling the safety cover 320 from the housing 302.

[0112] In some examples, the safety cover 320 can be an iris valve. For example, the safety cover 320 can be an iris valve that covers a bottom surface of the drug cartridge base 318 when the iris valve is closed. In some examples, the iris valve includes an actuation mechanism. The actuation mechanism can include a force (e.g., translation) based mechanism. The actuation mechanism can be actuated by the connection of the holding chamber 200 to the housing 302. For example, when the holding chamber 200 is coupled to the housing 302 the holding chamber 200 can contact the actuation27106261231.6Atty. Docket No. 119186-TBD mechanism, thereby causing the iris valve to transition to the open state. In this manner, the drug cartridge base 318 cannot be exposed to the vaporizer until the holding chamber 200 is coupled to the drug assembly 300.

[0113] In some examples, the function of the safety cover 320 can be replaced by a sensor within the vaporizer. The sensor can be operable to detect the presence of the holding chamber 200. In some examples, the sensor can include RFID readers and / or optical sensors. In some examples, the sensor can prevent delivery of heated air (described further herein) until the holding chamber 200 is confirmed to be attached to the drug assembly 300 and thereby the vaporizer. In some examples, the sensor can prevent delivery of heated air until the holding chamber 200 is confirmed to be attached to vaporizer (e.g., the holding chamber 200 is in fluid communication with the vaporizer). In some examples, the sensor can infer that the holding chamber 200 is attached to the vaporizer (e.g., the holding chamber 200 is in fluid communication with the vaporizer) when the sensor detects that the holding chamber is sufficiently close (e.g., proximal) to the vaporizer. For example, the finger grips 203(a), 203(b) of the holding chamber 200 can include RFID tags operable to provide a location of the finger grips 203(a), 203(b) with respect to the vaporizer and / or drug assembly 300.

[0114] In some examples, the safety cover 320 can provide a tamper-resistant feature to the drug assembly 300, thereby preventing unapproved or inappropriate access to the drug within the drug cartridge 312. For example, the safety cover 320 can be configured such that the safety cover 320 can only be uncoupled from the housing 302 by coupling the holding chamber 200 to the housing 302. In some examples, the specific dimensions of the holding chamber 200 (e.g., the first finger grip 203(a) and the second finger grip 203(b)) can be configured such that the holding chamber 200 is operable to uncouple the safety cover 320 from the housing 302, but other forces (e.g., pulling the safety cover 320, etc.) are not operable to remove the safety cover 320 from the housing 302.

[0115] In some examples, the drug assembly 300 can include additional features that provide tamper-resistance. For example, the drug can be inaccessible to a user when it is housed within the drug cartridge 312. In some examples, the drug cartridge 312 cannot be removed from the housing 302 without the use of specialist tools or destruction of the drug assembly 300. In some examples, the drug cartridge base 318 and the chimney 31428106261231.6Atty. Docket No. 119186-TBD cannot be separated by hand (e.g., specialized equipment must be used to apply sufficient force or the drug cartridge 312 must be destroyed or cut open to expose the fiber pad 316, which risks contamination and / or loss of the drug). The drug coats the fiber pad 316 in a thin layer throughout the porous volume of the fiber pad 316, thereby necessitating removal by scraping or dissolving, which risks contamination and / or loss of the drug substance. For example, necessitating removal of the drug by scraping or dissolving can act as a deterrent / tamper-resistant feature (e.g., contamination and / or loss of drug substance can make removal by scraping or dissolving useless).

[0116] In some examples, the drug assembly 300 can be packaged separately from the holding chamber 200 for transportation. By packaging the drug assembly 300 and the holding chamber 200 separately, a user is prevented from accessing the drug within the drug assembly 300 without also acquiring a holding chamber 200.

[0117] When the holding chamber 200 is coupled to the drug assembly 300, one of the posts 326(a), 326(b) can provide a force to the linkage arm 206 to actuate the valve 214 to the open state. One of the posts 326(a), 326(b) can provide a force to translate the linkage arm 206 towards the aerosol containment portion 204. The linkage arm 206 can cause the circular portion 207 of the valve arm 209 to slide downward in the slot 211 , thereby causing the valve arm 209 to swing upward and actuate the valve 214 to the open state (e.g., not sealed to the lumen 208).

[0118]

[0119] FIG. 13A illustrates the drug cartridge 312 coupled to the housing 302. As illustrated, the cartridge base 318 can include a lip 328. As illustrated in FIG. 13B, the cartridge base 318 can be inserted or slid into the housing 302 and the lip 328 can be inserted past housing clips 331 (a), 331 (b). Once the lip 328 is inserted past clips 331(a), 331 (b), the clips 331 (a), 331 (b) can lock into place, thereby securing the drug cartridge 312 within the housing 302. In some examples, a secondary seal 330(a), 330(b) can provide an airtight seal between the drug cartridge 312 and a vaporizer attachment port. In some examples, the secondary seal 330(a), 330(b) can provide an airtight seal between the housing 302 and the drug cartridge 312. In some examples, the secondary seal 330(a), 330(b) can be a silicone seal. In some examples, the cartridge base can include a taper 332 (taper 332 is also referred to herein as a tapered base or a bottom29106261231.6Atty. Docket No. 119186-TBD tapered edge). In some examples, the taper 332 can be about 30 degrees to about 60 degrees. In some examples, the taper 332 can be about 45 degrees. The taper 332 can allow for an airtight seal with a vaporizer as described further herein.

[0120] As described further herein, the drug cartridge 312 can be configured to be heated by a vaporizer. When a user removes the drug assembly 300 from the vaporizer, the drug cartridge 312 may retain heat, such that there is a bum risk to the user if the user contacts the drug cartridge 312. To overcome the bum risk, the drug cartridge 312 can include a bottom surface 334 that is recessed within the housing 302. In this manner, the bottom surface 334 is more difficult for a user to accidentally contact, thereby reducing bum risk. Further, the first drug assembly finger grip 306(a) and the second drug assembly finger grip 306(b) can be heat resistant, as described herein, thereby reducing and / or preventing bum risk. The bottom surface 334 can also be recessed within the housing 302 to reduce the risk of contamination during use. For example, the thermal connection between the bottom surface 334 of the drug cartridge 312 and the vaporizer can be contained within the housing 302. In this manner, the housing 302 can provide a barrier to the external environment, thereby preventing contamination of the drug cartridge 312 during use.

[0121] The safety cover 320 can prevent the drug assembly 300 from being attached to the vaporizer prior to attachment of the holding chamber 200 to the drug assembly 300. For example, as described further herein, the tabs 308(a), 308(b) of the drug assembly 300 can be configured to couple with corresponding recesses at the end of a vaporizer to couple the drug assembly 300 to the vaporizer. The safety cover 320 can prevent the tabs 308(a), 308(b) from accessing the recesses and / or the groove leading to the recesses of the vaporizer. For example, as illustrated in FIG. 13C, the safety cover 320 covers the tabs 308(a), 308(b), such that the tabs 308(a), 308(b) cannot be vertically received within the groove of the vaporizer (e.g., the drug assembly 300 cannot be properly seated within the vaporizer to allow the tabs 308(a), 308(b) to be received within a groove). For example, to attach the drug assembly 300 to the vaporizer, a user is required to translate the tabs 308(a), 308(b) downward through openings of a vaporizer attachment port to the groove and then rotate the drug assembly 300 to lock the tabs 308(a), 308(b) within the recesses. The safety cover 320 can prevent (e.g., block) the downward motion of the tabs 308(a), 308(b) into the groove. Thus, a user is required to first install the holding chamber30106261231.6Atty. Docket No. 119186-TBD200, thereby removing the safety cover 320, before the tabs 308(a), 308(b) can be rotated into the recesses.

[0122] As illustrated in FIG. 13D, once the safety cover 320 is removed, downward motion of the tabs 308(a), 308(b) is no longer blocked by the safety cover 320. The safety cover 320 prevents improper installation of the drug assembly 300 into the vaporizer without first attaching the holding chamber 200. The holding chamber 200 must first be coupled to the drug assembly 300, thereby releasing the safety cover 320 from the drug assembly 300. The tabs 308(a), 308(b) are then sufficiently exposed such that the tabs 308(a), 308(b) may slide within the groove of the vaporizer. In this manner, improper use of the drug assembly 300 and vaporizer is prevented (e.g., the drug held in the drug assembly 300 cannot be heated by the vaporizer until the safety cover 320 is removed which requires the holding chamber 200 to be coupled to the drug assembly 300), thereby ensuring that the aerosolized drug is entirely contained within the holding chamber 200.

[0123] FIG. 14 illustrates a vaporizer 400. The vaporizer 400 can be configured to provide heated air to the drug on the fiber pad 316, thereby aerosolizing the drug into the holding chamber 200. The vaporizer 400 can have a drug assembly attachment port 402. The drug assembly attachment port 402 can comprise an attachment mechanism operable to couple to the drug assembly 300. For example, the drug assembly attachment port 402 can include one or more openings for receiving the at least one mating mechanism of the housing 302 of the drug assembly 300. In some examples, the drug assembly attachment port 402 can include a first opening 406(a) and a second opening 406(b). The first opening 406(a) can be configured to receive tab 308(a) of the housing 302. The second opening 406(b) can be configured to receive tab 308(b) of the housing 302. The drug assembly attachment port 402 can include a groove 404. The first opening 406(a) and the second opening 406(b) can have a sufficient height (e.g., distance from an upper edge of the openings to the groove 404) such that the tabs 308(a), 308(b) cannot reach the groove 404 unless the safety cover 320 is removed from the drug assembly 300 (e.g., by attaching the holding chamber 200). The groove 404 can include two recesses which the tabs 308(a), 308(b) can slide and snap (e.g., lock) into when the drug assembly 300 is rotated along the groove 404. The recesses can lock the tabs 308(a), 308(b) into place, thereby coupling the drug assembly to the vaporizer 400. In some examples, the groove31106261231.6Atty. Docket No. 119186-TBD404 can be a quarter turn threaded ramp configured to ensure compression is applied to the drug assembly 300 for a secure and sealed attachment to the drug assembly attachment port 402.

[0124] In some examples, the drug assembly 300 can only be removed from the drug assembly attachment port 402 by providing a force to the first drug assembly finger grip 306(a) and the second drug assembly finger grip 306(b), thereby moving the tab bodies 307(a), 307(b) outward and unlocking the tabs 308(a), 308(b) from the recesses in the groove 404. In some examples, the holding chamber 200 must be removed from the drug assembly 300 prior to the drug assembly 300 being removed from the vaporizer. For example, as illustrated in FIG. 12, when the holding chamber 200 is coupled to the drug assembly 300, the first drug assembly finger grip 306(a) and the second drug assembly finger grip 306(b) can be housed within the receiving portion 202 of the holding chamber 200. In this manner, it is ensured that the holding chamber 200 must be removed from the drug assembly 300 before the drug assembly 300 is removed from the vaporizer 400. For example, when the holding chamber 200 is coupled to the drug assembly 300, the first drug assembly finger grip 306(a) and the second drug assembly finger grip 306(b) are inaccessible to the user as they are housed within the receiving portion 202 of the holding chamber 200. The holding chamber 200 may be removed from the drug assembly 300 by compressing the first finger grip 203(a) and the second finger grip 203(b), thereby releasing the tabs 205(a), 205(b) from the first opening 304(a) and the second opening 304(b), respectively. A user may then lift the holding chamber 200 upward away from the drug assembly 300. By requiring the holding chamber 200 to be removed from the drug assembly 300 prior to the drug assembly 300 being removed from the vaporizer 400, it is ensured that the valve 214 of the holding chamber 200 is closed. Further, removing the holding chamber 200 prior to removal of the drug assembly 300 from the vaporizer 400 prevents aerosol exposure from the underside (e.g., open cartridge base 318) is prevented.

[0125] Removing the holding chamber 200 from the drug assembly 300 prior to removal of the drug assembly 300 from the vaporizer 400 ensures that the valve 214 reverts back to the closed position, thereby preventing escape of aerosolized drug from the holding chamber 200. Removing the holding chamber 200 from the drug assembly 300 before32106261231.6Atty. Docket No. 119186-TBD removing the drug assembly from the vaporizer 400 allows the mouthpiece 100 to be attached to the holding chamber 200 without having to remove the drug assembly 300. In this manner, an additional step (e.g., removal of the drug assembly 300 from the holding chamber 200 after removal of both the holding chamber and drug assembly 300, as coupled together, from the vaporizer 400) is prevented. The process of removing the holding chamber 200 from the drug assembly 300 before the drug assembly 300 is removed from the vaporizer 400 further prevents the risk of inadvertently presenting the patient with a heated drug assembly 300.

[0126] In conjunction with, or as alternatives to, the first drug assembly finger grip 306(a) and the second drug assembly finger grip 306(b) being housed in the receiving portion 202 of the holding chamber 200 when the holding chamber 200 is coupled to the drug assembly 300, other structures, features, and methods can be used to prevent detachment of the drug assembly 300 from the vaporizer 400 before the holding chamber 200 is detached from the drug assembly 300. For example, the holding chamber 200 can be coupled to the drug assembly 300 via a twisting (e.g., screwing) motion in a first direction (e.g., clockwise or counterclockwise). The drug assembly 300 can be coupled to the vaporizer 400 via a twisting (e.g., screwing) motion in a second direction. The second direction can be opposite (e.g., clockwise or counterclockwise) from the twisting (e.g., screwing) motion of the first direction. For example, the holding chamber 200 and the drug assembly 300 can be threaded counter to a threading between the drug assembly 300 and the vaporizer 400. In this manner, the holding chamber 200 must first be rotated to remove the holding chamber 200 from the drug assembly 300 before the drug assembly 300 is rotated in an opposite direction to remove the drug assembly 300 from the vaporizer 400. In some examples, the drug assembly 300 can be shrouded entirely within the holding chamber 200. For example, the holding chamber 200 can form a mechanical interconnect with a portion of the vaporizer 400. The drug assembly 300 can form a friction fit with a separate portion of the vaporizer 400, such that the drug assembly 300 remains connected to the vaporizer 400 when the holding chamber 200 is removed from the vaporizer.

[0127] When the holding chamber 200 is removed from the drug assembly 300, the posts 326(a), 326(b) are removed from contact with the linkage arm 206, thereby returning the33106261231.6Atty. Docket No. 119186-TBD valve 214 to the closed state as described herein. When the valve 214 is in the closed state, the lumen 208 of the holding chamber 200 is sealed, thereby preventing the contents (e.g., aerosolized drug) of the aerosol containment portion 204 from being expelled from the aerosol containment portion 204. In this manner, the aerosolized drug is prevented from escaping to the atmosphere before it is delivered to a patient.

[0128] To remove the drug assembly 300 from the vaporizer 400, a force is applied to the first drug assembly finger grip 306(a) and the second drug assembly finger grip 306(b), the tabs 308(a), 308(b) move outward (e.g., away from a center of the drug assembly housing 302). For example, when the tabs 308(a), 308(b) are connected to the corresponding recesses (e.g., recess 414) applying a force (e.g., via a user’s fingers) to the first drug assembly finger grip 306(a) and the second drug assembly finger grip 306(b) can release the tabs 308(a), 308(b) from the recesses (e.g., recess 414). For example, a user can squeeze the first drug assembly finger grip 306(a), and the second drug assembly finger grip 306(b) inward such that the tabs 308(a), 308(b) are disengaged from the recesses (e.g., recess 414). A user can then rotate the drug assembly 300 such that the tabs 308(a), 308(b) translate along the groove 404 away from the recesses (e.g., recess 414). A user can then lift the drug assembly 300 away from the vaporizer 400 such that the tabs 308(a), 308(b) translate out of the openings 406(a), 406(b), thereby uncoupling the drug assembly 300 from the vaporizer 400. In other examples, squeezing the first drug assembly finger grip 306(a) and the second drug assembly finger grip 306(b) can provide sufficient clearance (e.g., the tabs 308(a), 308(b) are outside of the groove 404) such that a user can simply lift the drug assembly 300 away from the vaporizer 400.

[0129] In some examples, the vaporizer 400 can include a pump operably to provide air to the vaporizer 400. The pump can be configured to provide a flow of air that is heated by the vaporizer 400 and thereby heats the drug contained on the fiber pad 316. In some examples, the pump can include an expansion chamber located on the pump outlet. The expansion chamber can be configured to provide a smooth air flow rate with little or no oscillation. In this manner, the flow rate of air can be precisely controlled through the vaporizer 400.

[0130] FIG. 15 illustrates the internal components of the holding chamber 200 coupled to the drug assembly 300 which is coupled to the drug assembly attachment port 402 of the34106261231.6Atty. Docket No. 119186-TBD vaporizer 400. As illustrated, the drug assembly 300 is attached to vaporizer via the tabs 308(a), 308(b) which are locked into corresponding recesses of the groove 404. The first drug assembly finger grip 306(a) and the second drug assembly finger grip 306(b) are housed within (e.g., shrouded by) the receiving portion 202 of the holding chamber 200.

[0131] By housing the first drug assembly finger grip 306(a) and the second drug assembly finger grip 306(b) within the receiving portion 202 of the holding chamber 200, a user cannot remove the drug assembly 300 from the vaporizer 400 until the holding chamber 200 is first removed from the drug assembly 300. Ensuring removal of the holding chamber 200 from the drug assembly 300 before removal of the drug assembly 300 from the vaporizer 400 is important to contain the aerosolized drug in the holding chamber 200 and prevent contamination of the external environment with the aerosolized drug. For example, as described herein, when the holding chamber 200 is attached to the drug assembly 300, one of the posts 326(a), 326(b) contacts the linkage arm 206 such that the valve 214 is in the open state (e.g., the lumen 208 is open such that the aerosolized drug can transfer into and / or out of the holding chamber 200). To transition the valve 214 back to the closed state, thereby sealing the aerosolized drug in the holding chamber 200, the holding chamber 200 must be removed from the drug assembly 300 to remove the force of the posts 326(a), 326(b) from the linkage arm 206. By concealing the first drug assembly finger grip 306(a) and the second drug assembly finger grip 306(b) within the receiving portion 202 of the holding chamber 200, it is ensured that a user must first remove the holding chamber 200 from the drug assembly 300, thereby closing the valve 214 and sealing the aerosolized drug in the holding chamber 200, before the first drug assembly finger grip 306(a) and the second drug assembly finger grip 306(b) can be accessed to remove the drug assembly 300 from the vaporizer 400. In this manner, containment of the aerosolized drug within the holding chamber 200 is ensured and contamination of the external environment is prevented.

[0132] The taper 332 of the cartridge base 318 can provide a seal with the interior components of the vaporizer 400. The taper 332 can improve the seal with the vaporizer heating column 410 and prevent the drug assembly 300 from getting stuck in the vaporizer heating column 410.35106261231.6Atty. Docket No. 119186-TBD

[0133] In some examples, the vaporizer heating column 410 can be aluminum. In some examples, the various mating mechanisms, attachment mechanisms, and engagement features described herein can be aluminum, stainless-steel, or other materials. The lumen 208 of the holding chamber 200 can be a hard thermoplastic such as, for example, polypropylene. The chimney 314 can be stainless steel. The stainless steel and / or aluminum material can have advantageous properties since these materials are less likely to generate particulates or off-gassing of volatile organic compounds when exposed to high temperatures. The o-ring 322 between the chimney 314 and the chimney channel 310 can provide an air gap which can reduce thermal transfer between the chimney 314 and the housing 302, holding chamber 200, and other components of the system, thereby preventing biocompatibility risks that might otherwise arise due to thermally driven particulate generation and off-gassing.

[0134] As discussed above, when the drug assembly 300 is coupled to the holding chamber 200, either post 326(a), 326(b) can provide a force to the linkage arm 206 of the holding chamber 200. The force can cause the linkage arm 206 to actuate the valve 214 to the open state. In this manner, the heating column 410 can provide heated air through the drug assembly 300 to the holding chamber 200. The heated air can aerosolize the drug held on the fiber pad 316 and move the aerosolized drug through the chimney 314 to the lumen 208 and into the aerosol containment portion 204 of the holding chamber 200.

[0135] FIGS. 16A-16B illustrate the holding chamber 200 and the drug assembly 300 being attached to the drug assembly attachment port 402. As illustrated, the tab 308(b) of the drug assembly 300 can be aligned with first opening 406(a) of the drug assembly attachment port 402. Similarly, the tab 308(a) of the drug assembly 300 can be aligned with the second opening 406(b) of the drug assembly attachment port 402. The tabs 308(a), 308(b) can be inserted through the first opening 406(a) and the second opening 406(b) and into the groove 404. The drug assembly 300 can then be rotated until the tabs 308(a), 308(b) lock (e.g., snap into) respective recesses of the groove 404 (e.g., recess 414). In some examples, the groove 404 can be sloped such that as the drug assembly 300 is rotated, the drug assembly 300 moves closer to (e.g., further within) the drug assembly attachment port 402 such that an airtight seal is formed between the vaporizer36106261231.6Atty. Docket No. 119186-TBD400 and the drug assembly 300. In some examples, the taper 332 of the cartridge base 318 can abut against a corresponding taper 405 of the heating column 410 to ensure effective conductive heating of the drug cartridge 312 (e.g., the fiber pad 316 and the drug contained thereon). The taper 332 and the taper 405 can further facilitate ease of detachment of the drug assembly 300 from the vaporizer 400.

[0136] Further, the secondary seal 330(a), 330(b) can provide an airtight seal between the drug assembly attachment port 402 of the vaporizer 400 and the housing 302 of the drug assembly 300 to ensure that all air from the vaporizer 400 flows through the cartridge base 318. The secondary seal 330(a), 330(b) can provide an airtight seal between the housing 302 and the cartridge 312 to ensure that all air from the vaporizer 400 flows through the cartridge base 318. In some examples, the secondary seal 330(a), 330(b) can be operable to provide an airtight seal such that even if gas leaks out of the drug cartridge 312, no gas is leaked out to the external environment (e.g., any leaking gas is trapped within the housing 302). FIG. 17 illustrates the fully coupled holding chamber 200, drug assembly 300, and drug assembly attachment port 402.

[0137] FIG. 18 illustrates a system 500 for aerosolizing a drug. The system 500 includes the holding chamber 200, the drug assembly 300, and the vaporizer 400. As illustrated, the holding chamber 200 can be coupled to the drug assembly 300. The drug assembly 300 can be coupled to the vaporizer 400. The system 500 can provide heated air to the drug contained in the drug assembly. The drug can then aerosolize and flow with the heated air into the holding chamber 200, thereby filling the holding chamber 200 with the aerosolized drug.

[0138] The vaporizer 400 can include a power source port. The power source port can be configured to receive electrical power from a power source. The vaporizer 400 can be powered by a battery or any other power source known in the art. The vaporizer 400 can include an on / off switch. The on / off switch can be configured to turn the vaporizer 400 on and off.

[0139] The vaporizer 400 can further include a fan located inside the vaporizer 400. The fan can provide cooling to the components of the vaporizer 400, thereby preventing the vaporizer 400 from overheating. The fan can be in fluid communication with a plurality of vent holes. The plurality of vent holes can allow air from the fan to exit the vaporizer 400.37106261231.6Atty. Docket No. 119186-TBDThe fan and plurality of vent holes can also be used to bring air into the vaporizer 400. For example, the fan can be configured to draw air from the external environment into the vaporizer 400. The air drawn into the vaporizer 400 can be heated and used as the vaporization volume of air. A pump can be used to provide a vaporization volume of air to the heated drug to form an aerosolized drug.

[0140] The heating element of the vaporizer 400 can be configured to provide heat to the drug cartridge 312 through the drug assembly attachment port 402. Once the drug assembly 300 and the holding chamber 200 are all coupled together and coupled to the vaporizer 400, the vaporizer 400 can provide heat to at least a portion of the drug cartridge 312 to influence aerosolization of the drug. The vaporizer 400 can also provide air flow (e.g., a vaporization volume of air) to the drug to move the aerosolized drug into the aerosol containment portion 204 of the holding chamber 200. The vaporizer can have a conductive column that heats the air to a vaporization temperature before the air is provided to the drug in the drug cartridge 312, thereby further influencing transition of the drug to an aerosolized drug. The vaporization volume of air can be passed over the conductive column, thereby heating the vaporization volume of air. The vaporization volume of air can spiral around the conductive column, entering at the bottom of the conductive column and exiting at the top. The vaporization volume of air and the heated drug cartridge 312 can influence, for example cause (e.g., trigger) the transition of the drug from a solid state to a vapor, which subsequently cools and condenses to form an aerosolized drug suspended in the vaporization volume of air. The aerosolized drug can be suspended in the vaporization volume of air flowing through the drug cartridge 312, thereby providing the aerosolized drug to the aerosol containment portion 204 of the holding chamber 200. The aerosolized drug can form from subsequent cooling and thermal condensation in the drug assembly 300 and in the aerosol containment portion 204 of the holding chamber.

[0141] In some examples, the vaporizer 400 can include one or more temperature sensors. The one or more temperature sensors can be configured to measure a temperature within the vaporizer 400. In some examples, the one or more temperature sensors can be in communication with the heating column 410 (e.g., operable to detect the temperature the heating column via a direct or indirect connection). In some38106261231.6Atty. Docket No. 119186-TBD examples, when the drug assembly 300 is coupled to the vaporizer 400, the one or more temperature sensors can measure a subtle temperature drop as the drug assembly 300 makes contact with the heating column 410 within the vaporizer 400 (e.g., through the cartridge base 318). The temperature drop can be indicative of correct installation of the drug assembly 300 (e.g., the heating column 410 is in fluid communication with the cartridge base 318, fiber pad 316, and chimney 314). In some examples, the heating column 410 can be preheated to a temperature prior to the drug assembly 300 being coupled to the vaporizer 400, preferably vaporization temperature of the drug to be aerosolized. In some examples, the heating column 410 must be preheated before the drug assembly 300 is coupled to the vaporizer 400. When the heating column 410 is preheated, the heating column can experience a temperature drop when the drug assembly 300 is connected due to the drug assembly 300 being at room temperature (e.g., lower temperature than the preheated temperature). In this manner, when the drug assembly 300 is coupled to the vaporizer 400, the one or more temperature sensors can be operable to detect the temperature drop, thereby providing an indication that the drug assembly 300 is properly installed in the vaporizer 400 (e.g., for a temperature drop to occur the cartridge base 318 must be in contact with the heating column 410). In some examples, the one or more temperature sensors can be located on or near a distal end of the heating column 410 (e.g., end nearest the drug assembly attachment port 402).

[0142] In some examples, the one or more temperature sensors can be in direct communication with the drug cartridge 312. For example, when the drug assembly 300 is correctly installed in the vaporizer 400, the drug cartridge 312 can contact a conductive contact point in the drug assembly attachment port 402 that is in communication with the one or more temperature sensors and isolated from the heating column 410. In some examples, the temperature of the drug cartridge 312 can be detected by non-contact means (e.g., infrared radiation). In some examples, the non-contact means can include a thermopile.

[0143] In some examples, the one or more temperature sensors in direct communication with the drug cartridge 312 can be located in the drug assembly 300 and receive electrical power only when the drug assembly 300 is correctly installed in the vaporizer 400. For39106261231.6Atty. Docket No. 119186-TBD example, pogo pin connectors or other electrical connectors can provide power from the vaporizer 400 to the one or more temperature sensors in the drug assembly 300.

[0144] The drug in the drug cartridge 312 within the drug assembly 300 is subjected to conductive heating and the drug is also subjected to convective heating by the heated vaporization volume of air. The conductive heating to the drug cartridge 312 is provided by a conductive column (e.g., heating column 410) within the vaporizer 400. The heating column 410 can be heated by a heating element of the vaporizer 400. The heating column 410 can include a taper 405 which abuts against the taper 332 of the cartridge base 318 to ensure effective conductive heating of the cartridge base 318 and thereby the fiber pad 316. The taper 405 and the taper 332 can abut against one another to ensure full contact of the heating column 410 with the cartridge base 318, thereby more efficiently heating the drug in the drug cartridge 312. The taper 405 and the taper 332 can ensure that the cartridge base 318 sits flush on the heating column 410, thereby ensuring efficient conductive heating. For example, the taper 405 and the taper 332 can allow for the cartridge base 318 to be in direct contact with the heating column 410. Conductive heating of the cartridge base 318, and thereby the fiber pad 316 holding the drug, can allow for production of an aerosolized drug with optimal properties for deep lung inhalation. For example, conductively heating the drug while it is on the fiber pad 316 allows the drug to vaporize more efficiently than when the drug is only heated by heated air (e.g., convectively). In some examples, the taper 405 can be about 45 degrees and the taper 332 can be about 45 degrees. In some examples, the taper 405 and the taper 332 can have corresponding angles summing to 90 degrees (e.g., 30 degrees and 60 degrees, both 45 degrees, etc.). The taper 405 and the taper 332 can be operable to improve thermal contact between the drug cartridge 312 and the heating column 410. The taper 405 and the taper 332 can be operable to improve ease of detachment of the drug assembly 300 from the vaporizer 400 (e.g., the taper 405 and taper 332 can prevent the cartridge base 318 from getting stuck in the heating column 410 due to thermal expansion). The taper 405 of the heating column 410 can also be referred to as an upper tapered edge.

[0145] Convective heating of the drug can be provided by the vaporization volume of air that spirals around the conductive column and then is carried through the drug cartridge40106261231.6Atty. Docket No. 119186-TBD312 to heat the drug. In an example, the conductive column is a solid column. In some examples, the conductive column can be a hollow column. In some examples, the hollow interior of the conductive column can be configured to receive a heating element for heating the conductive column. Both the vaporization volume of air and the drug cartridge 312 are provided heating by the conductive column. The drug is heated by both the conductive heating and the convective heating. The drug is heated to a vapor and then an aerosolized drug is formed in the holding chamber 200 due to subsequent thermal condensation of the vapor.

[0146] The heating element of the vaporizer 400 can provide heat at a temperature sufficient to aerosolize the drug in the drug cartridge 312 (e.g., vaporization temperature). For example, the vaporizer 400 can provide heat at a temperature of about 200 degrees Celsius (C) to about 260 degrees C. The vaporizer 400 can provide heat at a temperature of about 235 degrees C to the drug cartridge 312 and the vaporization volume of air. In some examples, the drug does not reach the set vaporization temperature. The flow of air to the drug can move the aerosolized drug to the aerosol containment portion 204 through the drug cartridge 312, housing 302, and receiving portion 202 (e.g., into the lumen 208). In some examples, the vaporizer 400 can provide an air flow rate of about 2 L / min to about 25 L / min. The vaporizer 400 can provide an air flow rate of about 2 L / min to about 3 L / min, about 3 L / min to about 4 L / min, about 4 L / min to about 5 L / min, about 5 L / min to about 6 L / min, about 6 L / min to about 7 L / min, about 7 L / min to about 8 L / min, about 8 L / min to about 9 L / min, about 9 L / min to about 10 L / min, about 10 L / min to about 11 L / min, about 11 L / min to about 12 L / min, about 12 L / min to about 13 L / min, about 13 L / min to about 14 L / min, about 14 L / min to about 15 L / min, about 15 L / min to about 16 L / min, about 16 L / min to about 17 L / min, about 17 L / min to about 18 L / min, about 18 L / min to about 19 L / min, about 19 L / min to about 20 L / min, about 20 L / min to about 21 L / min, about 21 L / min to about 22 L / min, about 22 L / min to about 23 L / min, about 23 L / min to about 24 L / min, about 24 L / min to about 25 L / min, or more. The air flow rate can be about 7 L / min. The vaporizer 400 can provide heat and air flow until the volume of the aerosolized drug and air in the aerosol containment portion 204 of the holding chamber 200 is about 1 L to about 3 L. The vaporizer 400 can provide heat and air flow until the41106261231.6Atty. Docket No. 119186-TBD volume of the aerosolized drug and air in the aerosol containment portion 204 of the holding chamber 200 is about 2 L.

[0147] The vaporizer 400 can heat the drug cartridge 312 and the vaporization volume of air and immediately begin filling the aerosol containment portion 204 with the aerosolized drug once the drug assembly 300 is coupled to the drug assembly attachment port 402 of the vaporizer 400. The vaporizer 400 can begin heating the drug cartridge 312 before providing an air flow. The vaporizer 400 can provide heat for a heating period and then provide air flow during a filling period (e.g., carrying the aerosolized drug into the aerosol containment portion 204 holding chamber 200 via the vaporization volume of air). The heating period can continue during the filling period. The heating period can be less than 30 seconds, about 30 seconds to about 1 minute, about 1 minute to about 2 minutes, about 2 minutes to about 3 minutes, about 3 minutes to about 4 minutes, about 4 minutes to about 5 minutes, or more. The filling period can be about 5 seconds to about 10 seconds, 10 seconds to about 20 seconds, about 20 seconds to about 30 seconds, about 30 seconds to about 40 seconds, about 40 seconds to about 50 seconds, about 50 seconds to about 1 minute, about 1 minute to about 2 minutes, or more. The heating period and the filling period can overlap. For example, the filling period can begin while the heating period is still in process.

[0148] After the aerosolized drug is filled into the holding chamber 200, the holding chamber 200 can be uncoupled from the drug assembly 300 and the vaporizer 400. As discussed above, the holding chamber can be uncoupled from the drug assembly 300 by compressing the finger grips 203(a), 203(b), thereby releasing the tabs 205(a), 205(b) from the openings 304(a), 304(b) in the drug assembly 300. The mouthpiece 100 can then be coupled to the holding chamber 200 using the one or more mating mechanisms of the holding chamber 200 and the mouthpiece 100, as discussed above. When the patient is ready to inhale the dose of the aerosolized drug, the patient can actuate the valve 214 in the holding chamber 200 by providing a force to the mouthpiece 100, as discussed above, and then inhale the aerosolized drug.

[0149] The finger grips 203(a), 203(b) can be held by the patient when the patient is ready to inhale the aerosolized drug. The patient may be instructed to hold the finger grips 203(a), 203(b) when handed the holding chamber 200. For example, by holding the finger42106261231.6Atty. Docket No. 119186-TBD grips 203(a), 203(b) rather than aerosol containment portion 204, it is ensured that there is no obstruction to the flow of aerosolized drug from the aerosol containment portion 204 through the mouthpiece 100. By holding the finger grips 203(a), 203(b), the aerosolized drug can freely move from the aerosol containment portion 204 through the lumen 208 and out the mouthpiece 100 due to the patient’s inhalation, rather than pushing the aerosolized drug out via a force provided by holding the aerosol containment portion 204. In this manner, it is ensured that the aerosolized drug is inhaled with the patient’s inhalation, instead of being forced out by a force on the aerosol containment portion 204. Holding the finger grips 203(a), 203(b) prevents the aerosolized drug from being released from the aerosol containment portion 204 too fast (e.g., via a holding force on the aerosol containment portion 204), which can waste the aerosolized drug (e.g., not all of the aerosolized drug is inhaled) and / or contaminate the external environment. Further, holding the finger grips 203(a), 203(b) improves useability (e.g., if held by the aerosol containment portion 204 the patient would not have control over the holding chamber 200 as the aerosol containment portion 204 is flexible).

[0150] Further provided herein is a method for engaging a mouthpiece to a holding chamber containing an aerosolized drug. FIG. 19 illustrates a flow chart of the method 1000. The method 1000 can begin at block 1002. At block 1002, the method 1000 can include engaging a portion of a mouthpiece over a receiving portion of the holding chamber. In some examples, engaging the mouthpiece to the receiving portion of the holding chamber includes coupling two or more engagement features to one or more projections (e.g., finger grips) of the holding chamber receiving portion.

[0151] At block 1004, the method 1000 can include rotating the mouthpiece in a direction to allow two or more engagement features to engage with a respective one of two or more finger grips of the holding chamber. In some examples, the two or more engagement features can include a first engagement feature and a second engagement feature. In some examples, the two or more engagement features can each include an arm having a tab at a distal end. The tabs can be configured to snap fit to the finger grips.

[0152] At block 1006, the method 1000 can include locking, when a lock portion of the two or more engagement features extends past the respective one of the two or more finger grips, the mouthpiece in an installed configuration. The lock portion can be tabs on the43106261231.6Atty. Docket No. 119186-TBD engagement features. The tabs can be configured to snap fit over the respective finger grips. In some examples, the lock portions can prevent the mouthpiece from rotating with respect to the holding chamber. In some examples, the lock portions prevent rotational displacement of the mouthpiece in relation to the holding chamber when the mouthpiece is in the installed configuration. In some examples, the lock portions allow movement (e.g., linear displacement) of the mouthpiece in relation to the holding chamber.

[0153] In some examples, blocks 1002, 1004, and 1006 of the method can be performed by a licensed healthcare professional.

[0154] In some examples, the method 1000 can further include pressing the mouthpiece in a direction towards the holding chamber and opening, when the mouthpiece is moved to an activated position by the pressing, a lumen formed in the mouthpiece and / or holding chamber for inhalation of the aerosolized therethrough. In some examples, the method 1000 can include instructing a patient to press the mouthpiece in the direction towards the holding chamber, thereby opening, when the mouthpiece is moved to the activated position by the pressing, a lumen formed in the mouthpiece and / or holding chamber for inhalation of the aerosolized drug therethrough. In some examples, pressing the mouthpiece towards the holding chamber opens a valve in the lumen. For example, pressing the mouthpiece towards the holding chamber causes a projection on the mouthpiece to contact a linkage arm, thereby opening a valve in the holding chamber and allowing the flow of aerosolized drug through the mouthpiece.

[0155] In some examples, the method 1000 can further include allowing continued inhalation through a plurality of atmospheric channels of the mouthpiece. For example, the method 1000 can include instructing a patient to continue to inhale through a plurality of atmospheric channels of the mouthpiece. The mouthpiece can include a plurality of atmospheric channels. The atmospheric channels can allow ambient air to be inhaled after the aerosolized drug has been evacuated from the holding chamber, thereby preventing a hard stop. Further, by allowing continued inhalation after the holding chamber is evacuated, the aerosolized drug can reach the patient’s deep lung region. For example, the patient can be instructed to continue pressing on the mouthpiece after the holding chamber has been substantially evacuated of the aerosolized drug. The lumen in44106261231.6Atty. Docket No. 119186-TBD the holding chamber can remain open while ambient air is inhaled through the plurality of atmospheric channels.

[0156] In some examples, the method 1000 can further include sealing the lumen when the holding chamber is substantially evacuated. In some examples, the method 1000 can include instructing the patient to seal the lumen when the holding chamber is substantially evacuated. In some examples, sealing the lumen comprises releasing the mouthpiece (e.g., discontinuing the pressing on the mouthpiece). In some examples, releasing the mouthpiece removes the force on the linkage arm, thereby causing the valve to return to a closed state.

[0157] Further provided herein is a method for administration of a drug to a patient in need thereof. FIG. 20 illustrates a method 1100 for administration of a drug to a patient in need thereof. The method 1100 can begin at block 1102. At block 1102, the method 1100 can include vaporizing a drug into an aerosol containment device coupled to a vaporizer. In some examples, the method 1100 can include coupling the aerosol containment device to a drug assembly containing a drug and coupling the drug assembly and the aerosol containment device to the vaporizer. The aerosol containment device can be a holding chamber for receiving the aerosolized drug. In some examples, the aerosol containment device can include one or more mating mechanisms configured to releasably couple to the drug assembly. In some examples, the drug assembly can include one or more mating mechanisms for releasably coupling to the vaporizer.

[0158] At block 1104, the method 1100 can include removing the aerosol containment device from the vaporizer. In some examples, removing the aerosol containment device from the vaporizer includes uncoupling the aerosol containment device from the drug assembly via the one or more mating mechanisms. In some examples, the one or more mating mechanisms include finger grips in mechanical communication with tabs. The tabs can couple to corresponding openings of the drug assembly. The finger grips can be compressed thereby releasing the tabs from the openings and uncoupling the aerosol containment device from the drug assembly.

[0159] At block 1106, the method 1100 can include engaging a portion of a mouthpiece over a receiving portion of the aerosol containment device. In some examples, the45106261231.6Atty. Docket No. 119186-TBD mouthpiece can include one or more mating mechanisms (e.g., engagement features) for coupling to the aerosol containment device.

[0160] At block 1108, the method 1100 can include rotating the mouthpiece in a direction to allow two or more engagement features to engage with a respective one of two or more finger grips of the aerosol containment device. In some examples, the two or more engagement features can include a first engagement feature and a second engagement feature. In some examples, the two or more engagement features can each include an arm having a tab at a distal end. The tabs can be configured to snap fit to the finger grips.

[0161] At block 1110, the method 1100 can include locking, when a locking portion of the two or more engagement features extends past the respective one of the two or more finger grips, the mouthpiece in an installed configuration. The lock portion can be tabs on the engagement features. The tabs can be configured to snap fit over the respective finger grips. In some examples, the lock portions can prevent the mouthpiece from rotating with respect to the aerosol containment device. In some examples, the lock portions prevent rotational displacement of the mouthpiece in relation to the aerosol containment device when the mouthpiece is in the installed configuration. In some examples, the lock portions allow movement (e.g., linear displacement) of the mouthpiece in relation to the aerosol containment device.

[0162] In some examples, blocks 1102, 1104, 1106, 1108, and 1110 can be performed by a licensed healthcare professional.

[0163] At block 1112, the method 1100 can include pressing the mouthpiece in a direction towards the aerosol containment device (e.g., holding chamber). In some examples, the method 1100 can include instructing a patient to press the mouthpiece in a direction towards the aerosol containment device (e.g., holding chamber). At block 1114, the method 1100 can include opening, when the mouthpiece is moved to an activated position by the pressing, a lumen in the mouthpiece for inhalation therethrough. In some examples, the lumen in the mouthpiece is opened by the patient when the patient is instructed to press the mouthpiece towards the aerosol containment device (e.g., holding chamber). In some examples, pressing the mouthpiece towards the aerosol containment device causes a projection on the mouthpiece to contact a linkage arm, thereby opening46106261231.6Atty. Docket No. 119186-TBD a valve in the aerosol containment device and allowing the flow of aerosolized drug through the mouthpiece.

[0164] At block 1116, the method 1100 can include activating or opening a plurality of atmospheric channels in the mouthpiece to allow continued inhalation. In some examples, the method 1100 can include instructing a patient to continue inhaling through the atmospheric channels in the mouthpiece. The method 1100 can facilitate continued inhalation of air from outside of the holding chamber via the plurality of atmospheric channels. The mouthpiece can include a plurality of atmospheric channels. The atmospheric channels can allow ambient air to be inhaled after the aerosolized drug has been inhaled, thereby preventing a hard stop and ensuring the aerosolized drug reaches the patient’s deep lung region. Preferably, the aerosolized drug reaches the patient’s alveoli.

[0165] At block 1118, the method 1100 can include sealing the lumen. In some examples, sealing the lumen comprises releasing the mouthpiece (e.g., discontinuing the pressing on the mouthpiece). In some examples, the method 1100 can include instructing a patient to seal the lumen by releasing the mouthpiece. In some examples, a licensed healthcare professional can instruct the patient to seal the lumen after one or more indicators (e.g., the indicators described herein) indicate that the aerosol containment portion has been completely evacuated. In some examples, releasing the mouthpiece removes the force on the linkage arm, thereby causing the valve to return to a closed state. In some examples, the lumen is sealed when inhalation is completed (e.g., the patient is finished inhaling which can include substantially evacuating the holding chamber and inhaling additional ambient air through the plurality of atmospheric channels). The additional ambient air can allow for different size lung capacities and / or assuring that the drug can reach a patient’s deep lung region. Preferably, the inhaled aerosolized drug reaches the patient’s respiratory bronchioles, alveolar ducts and / or alveoli for systemic absorption.

[0166] In some examples, the method 1100 can further include coupling the aerosol containment device to a drug assembly containing a drug and coupling the drug assembly and aerosol containment device to the vaporizer, prior to vaporizing the drug into the aerosol containment device. In some examples, the aerosol containment device includes one or more engagement features for coupling to one or more corresponding engagement47106261231.6Atty. Docket No. 119186-TBD features of the drug assembly. In some examples, coupling the aerosol containment device to the drug assembly causes a safety cover to be released from the drug assembly by the one or more engagement features of the aerosol containment device.

[0167] In some examples, coupling the drug assembly and aerosol containment device to the vaporizer includes inserting two or more attachment features (e.g., tabs mechanically connected to finger grips of the drug assembly) into a groove of the vaporizer and rotating the drug assembly and the aerosol containment device until the two or more attachment features (e.g., tabs) lock into a respective one of two or more recesses in the vaporizer.

[0168] In some examples, removing the aerosol containment device from the vaporizer includes removing the aerosol containment device from the drug assembly. In some examples removing the aerosol containment device from the drug assembly includes uncoupling at least one mating mechanism (e.g., tabs on finger grips) from the drug assembly. In some examples, pressing on the finger grips of the aerosol containment device releases the corresponding tabs from the corresponding openings of the drug assembly, thereby uncoupling the aerosol containment device from the drug assembly. In some examples, the drug assembly can remain coupled to the vaporizer when the aerosol containment device is removed from the vaporizer.

[0169] Further provided herein is a method for forming an aerosolized drug and administering the aerosolized drug to a patient in need thereof. FIG. 21 illustrates a method 1200 for forming an aerosolized drug and administering the aerosolized drug to the patient. The method 1200 can be conducted using the vaporizer, holding chamber, drug assembly, and mouthpiece described herein. The method 1200 generally describes an order of operations for using the components of the system described herein. In some examples, all steps of the method 1200 can be performed by a licensed healthcare professional.

[0170] At block 1202, the method 1200 can include preheating a vaporizer (e.g., the vaporizer described herein). Preheating the vaporizer can include preheating a heating column of a vaporizer as described herein. For example, the heating column can be preheated to any vaporization temperature and using any method described herein. In some examples, the vaporizer must be preheated before the remaining steps of the method 1200 are conducted.48106261231.6Atty. Docket No. 119186-TBD

[0171] At block 1204, the method 1200 can include attaching a holding chamber to a drug assembly containing a drug, thereby releasing a safety cover from the drug assembly. In some examples, the holding chamber must be attached to the drug assembly before the remaining steps of the method 1200 are conducted. The holding chamber can be the holding chamber described herein and the drug assembly can be the drug assembly described herein. Attaching the holding chamber to the drug assembly can include inserting one or more finger grips of the holding chamber into one or more openings of the drug assembly, thereby locking one or more tabs into the openings, as described herein. Attaching the holding chamber to the drug assembly releases the safety cover of the drug assembly, as described herein. In some examples, attaching the holding chamber to the drug assembly, thereby releasing the safety cover, must be completed before the remaining steps of the method 1200 are conducted.

[0172] At block 1206, the method 1200 can include attaching the holding chamber and the drug assembly to the preheated vaporizer. In some examples, the holding chamber and the drug assembly must be attached to the preheated vaporizer before the remaining steps of the method 1200 are conducted. In some examples, attaching the holding chamber and the drug assembly to the vaporizer includes inserting one or more tabs of the drug assembly into a groove of the vaporizer, as described herein. Attaching the holding chamber and the drug assembly to the vaporizer can further include rotating the holding chamber and the drug assembly such that the one or more tabs of the drug assembly lock in place in recesses within the groove, as described herein.

[0173] At block 1208, the method 1200 can include vaporizing the drug into the holding chamber. In some examples, vaporizing the drug into the holding chamber must occur before the remaining steps of the method 1200 are conducted. In some examples, vaporizing the drug into the holding chamber includes conductive and convective heating of the drug, as described herein. In some examples, the drug subsequently cools and condenses, thereby forming an aerosolized drug.

[0174] At block 1210, the method 1200 can include detaching the holding chamber from the drug assembly. In some examples, detaching the holding chamber from the drug assembly can be conducted using any of the detachment methods for the holding chamber described herein. For example, detaching the holding chamber from the drug49106261231.6Atty. Docket No. 119186-TBD assembly can include compressing finger grips from the holding chamber, thereby releasing tabs from the openings of the drug assembly. The holding chamber can then be lifted away from the drug assembly and vaporizer. In some examples, the holding chamber must be detached from the drug assembly before the remaining steps of the method 1200 can be conducted. In some examples, as described herein, the drug assembly cannot be removed from the vaporizer until the holding chamber is removed from the drug assembly. For example, the mechanisms (e.g., drug assembly finger grips) for removing the drug assembly from the vaporizer can be shrouded (e.g., hidden) within the holding chamber, such that the holding chamber must be removed from the drug assembly before the mechanisms for removing the drug assembly from the vaporizer can be accessed. The drug assembly can be removed from the vaporizer at any time after the holding chamber is removed from the drug assembly. In some examples, the drug assembly can be removed from the vaporizer as described herein.

[0175] At block 1212, the method 1200 can include attaching a mouthpiece to the holding chamber. For example, attaching the mouthpiece to the holding chamber can be conducted by the two step attachment process described herein (e.g., engaging the mouthpiece to the receiving portion of the holding chamber and twisting the locking portions of the mouthpiece in place over the holding chamber finger grips). In some examples, the mouthpiece must be attached to the holding chamber before the remaining steps of the method 1200 can be conducted. Attaching a mouthpiece to the holding chamber can also be referred to as installing a mouthpiece to the holding chamber.

[0176] In some examples, when the mouthpiece is attached to the holding chamber, the method 1200 can include providing the holding chamber with the attached mouthpiece to the patient. In some examples, the method 1200 can further include providing instructions to the patient.

[0177] At block 1214, the method 1200 can include instructing a patient to activate a valve in the holding chamber and inhale the aerosolized drug from the holding chamber (e.g., via the mouthpiece). In some examples, activating the valve can be conducted as described herein. For example, activating the valve can be accomplished by pressing the mouthpiece inward towards the holding chamber. The patient can then inhale the50106261231.6Atty. Docket No. 119186-TBD aerosolized drug from the holding chamber. In some examples, the patient can inhale past the total volume in the holding chamber via the atmospheric channels.

[0178] At block 1216, the method 1200 can include verifying evacuation of the aerosolized drug from the holding chamber. In some examples, verifying evacuation of the aerosolized drug form the holding chamber can include palpating the aerosol containment portion of the holding chamber and / or observing one of the indicators of complete evacuation of the aerosolized drug described herein.

[0179] In some examples, the method 1200 can include instructing the patient to deactivate the valve. In some examples, deactivating the valve can include discontinuing the pressing on the mouthpiece, as described herein. For example, the patient can be instructed to discontinue pressing the mouthpiece towards the holding chamber.

[0180] It will be appreciated that the method 1200 is provided as an order of operations for administering an aerosolized drug to a patient in need thereof. In some examples, the steps of the method 1200 must be conducted in order (e.g., block 1202 first followed by the remaining blocks) for the various reasons described herein (e.g., safety reasons, etc.).

[0181] Illustrative aspects of the present disclosure include:

[0182] Aspect 1 . A method for coupling and / or operation of a mouthpiece in relation to a holding chamber containing an aerosolized drug, the method comprising engaging a portion of the mouthpiece over a receiving portion of the holding chamber; rotating the mouthpiece in a direction to allow two or more engagement features to engage with a respective one of two or more finger grips of the holding chamber; and locking, when a locking portion of the two or more engagement features extends past the respective one of the two or more finger grips, the mouthpiece in an installed configuration.

[0183] Aspect 2. The method of Aspect 1 , wherein the installed configuration prevents rotational displacement of the mouthpiece in relation to the holding chamber.

[0184] Aspect 3. The method of Aspect 1 or 2, wherein the installed configuration allows linear displacement of the mouthpiece in relation to the holding chamber, optionally wherein portions of the two or more engagement features are configured to translate along slots in the receiving portion.

[0185] Aspect 4. The method of any one of Aspects 1-3, the method further comprising instructing a patient to press the mouthpiece in a direction towards the holding chamber,51106261231.6Atty. Docket No. 119186-TBD thereby opening, when the mouthpiece is moved to an activated position by the pressing, a lumen formed in the aerosol containment portion for inhalation of the aerosolized drug therethrough.

[0186] Aspect 5. The method of Aspect 4, the method further comprising instructing the patient to continue inhaling through a plurality of atmospheric channels of the mouthpiece.

[0187] Aspect 6. The method of Aspect 4 or 5, the method further comprising instructing the patient to discontinue the pressing on the mouthpiece, thereby moving a valve in communication with the lumen to an inactivated position and sealing the lumen, optionally wherein the valve is naturally in a closed state.

[0188] Aspect 7. The method of any one of Aspects 4-6, wherein pressing the mouthpiece towards the holding chamber moves a valve in communication with the lumen to an activated position, thereby unsealing the lumen.

[0189] Aspect 8. A method for administration of a drug to a patient in need thereof, the method comprising: vaporizing a drug into a holding chamber coupled to a vaporizer; removing the holding chamber from the vaporizer; coupling a portion of a mouthpiece to a receiving portion of the holding chamber.

[0190] Aspect 9: The method of Aspect 8, further comprising instructing the patient to open a lumen in the holding chamber.

[0191] Aspect 10. The method of Aspect 9, wherein opening the lumen provides fluid communication between the aerosol containment portion of the holding chamber and the mouthpiece for inhalation therethrough.

[0192] Aspect 11. The method of any one of Aspects 8-10, wherein the coupling of the mouthpiece to the receiving portion of the holding chamber prevents unintended actuation of a valve in the holding chamber.

[0193] Aspect 12. The method of any one of Aspects 8-11 , wherein coupling the portion of the mouthpiece to the receiving portion of the holding chamber includes a two-step attachment process.

[0194] Aspect 13. The method of Aspect 12, wherein the two-step attachment process includes engaging the mouthpiece with a portion of the receiving portion of the holding chamber; and rotating the mouthpiece in a direction to allow two or more engagement features to engage with a respective one of two or more finger grips of the holding52106261231.6Atty. Docket No. 119186-TBD chamber; wherein the rotating causes the mouthpiece to lock in an installed configuration when a locking portion of the two or more engagement features extends past the respective one of the two or more finger grips.

[0195] Aspect 14. The method of Aspect 13, wherein engaging the mouthpiece with a portion of the receiving portion of the holding chamber includes inserting the mouthpiece into a portion of the receiving portion of the holding chamber.

[0196] Aspect 15. The method of any one of Aspects 12-14, wherein linear motion of the mouthpiece with respect to the holding chamber is restricted until the two-step attachment process is completed.

[0197] Aspect 16. The method of any one of Aspects 9-15, wherein instructing the patient to open the lumen in the mouthpiece includes instructing the patient to press the mouthpiece in a direction towards the holding chamber, wherein the pressing actuates a valve in fluid communication with the lumen to an open state.

[0198] Aspect 17. The method of any one of Aspects 10-16, the method further comprising instructing the patient to continue inhalation via a plurality of atmospheric channels.

[0199] Aspect 18. The method of any one of Aspects 10-17, the method further comprising instructing the patient to seal the lumen when inhalation is completed.

[0200] Aspect 19. The method of any one of Aspects 8-18, the method further comprising: coupling the holding chamber to a drug assembly containing a drug; and coupling the drug assembly and the holding chamber to the vaporizer, prior to vaporizing the drug into the holding chamber.

[0201] Aspect 20. The method of any one of Aspects 8-19, the method further comprising: coupling the holding chamber to a drug assembly containing a drug; and subsequent to coupling the holding chamber to the drug assembly, coupling the holding chamber and the drug assembly to the vaporizer.

[0202] Aspect 21. The method of Aspect 19 or 20, wherein coupling the holding chamber to the drug assembly releases a safety cover from the drug assembly.

[0203] Aspect 22. The method of Aspect 21 , wherein the safety cover prevents attachment of the drug assembly to the vaporizer until the safety cover is removed and / or released.53106261231.6Atty. Docket No. 119186-TBD

[0204] Aspect 23. The method of any one of Aspects 19-22, wherein coupling the drug assembly and the holding chamber to the vaporizer comprises: inserting two or more attachment features into a groove of the vaporizer; and rotating the drug assembly and holding chamber until the two or more attachment features lock into a respective one of two or more recesses of the vaporizer.

[0205] Aspect 24. The method of any one of Aspects 19-23, wherein removing the holding chamber from the vaporizer comprises removing the holding chamber from the drug assembly.

[0206] Aspect 25. The method of Aspect 24, wherein the drug assembly remains coupled to the vaporizer after the holding chamber is removed from the vaporizer.

[0207] Aspect 26. The method of any one of Aspects 19-25, wherein the vaporizer is heated to a vaporization temperature prior to coupling the drug assembly and the aerosol containment device to the vaporizer.

[0208] Aspect 27. The method of Aspect 26, wherein the holding chamber is coupled to the drug assembly prior to heating the vaporizer to the vaporization temperature.

[0209] Aspect 28. The method of Aspect 26 or 27, wherein coupling the drug assembly to the vaporizer causes a temperature drop within the vaporizer.

[0210] Aspect 29. The method of Aspect 28, wherein the temperature drop occurs on or within a heating column of the vaporizer.

[0211] Aspect 30. The method of Aspect 28 or 29, wherein the temperature drop indicates that the drug assembly is properly coupled to the vaporizer.

[0212] Aspect 31. The method of any one of Aspects 13-30, wherein the installed configuration prevents rotational movement of the mouthpiece in relation to the holding chamber.

[0213] Aspect 32. The method of any one of Aspects 16-31 , wherein pressing the mouthpiece in the direction towards the holding chamber includes linearly translating the mouthpiece along the two or more finger grips.

[0214] Aspect 33. The method of any one of Aspects 9-32, wherein opening the lumen comprises actuating a valve of the holding chamber by pressing the mouthpiece in the direction towards the holding chamber.54106261231.6Atty. Docket No. 119186-TBD

[0215] Aspect 34. A drug assembly configured to contain a drug, the drug assembly comprising: a drug cartridge; a housing operable to contain the drug cartridge and releasably couple to a holding chamber and / or a vaporizer, the housing comprising at least one mating mechanism; and a safety cover releasably coupled to the housing, wherein the safety cover detaches from the housing when the housing is releasably coupled to the holding chamber.

[0216] Aspect 35. The drug assembly of Aspect 34, wherein the safety cover is coupled to the housing prior to filling the drug cartridge with the drug.

[0217] Aspect 36. The drug assembly of Aspect 34 or 35, wherein the drug assembly is prevented from being uncoupled from the vaporizer until the holding chamber is uncoupled from the drug assembly.

[0218] Aspect 37. The drug assembly of any one of Aspects 34-36, wherein the safety cover prevents attachment of the drug assembly to the vaporizer until the safety cover is removed from the housing.

[0219] Aspect 38. The drug assembly of any one of Aspects 34-37, wherein the at least one mating mechanism comprises a first mating mechanism and a second mating mechanism, the first mating mechanism and the second mating mechanism operable to releasably couple to two or more corresponding mating mechanisms of the holding chamber.

[0220] Aspect 39. The drug assembly of Aspect 38, wherein the first mating mechanism and the second mating mechanism comprise ledges operable to receive the two or more corresponding mating mechanisms of the holding chamber, optionally wherein the first mating mechanism comprises a first opening and the second mating mechanism comprises a second opening, the first opening and second opening each having a ledge and wherein the corresponding mating mechanisms of the holding chamber comprise a first finger grip and a second finger grip, the first and second finger grips each comprising a tab, and wherein the first opening is configured to releasably couple with the tab of the first finger grip and the second opening is configured to releasably couple with a tab of the second finger grip.

[0221] Aspect 40. The drug assembly of any one of Aspects 34-39, wherein the at least one mating mechanism further comprises a third mating mechanism and a fourth mating55106261231.6Atty. Docket No. 119186-TBD mechanism, the third mating mechanism and the fourth mating mechanism operable to releasably couple to a groove of the vaporizer.

[0222] Aspect 41. The drug assembly of Aspect 40, wherein the third mating mechanism and the fourth mating mechanism comprise tabs operable to slide along the groove of the vaporizer and lock into place in corresponding recesses of the groove of the vaporizer.

[0223] Aspect 42. The drug assembly of any one of Aspects 34-41 , wherein the drug assembly is configured to be coupled to the vaporizer after a heating column of the vaporizer is preheated to a vaporization temperature.

[0224] Aspect 43. The drug assembly of any one of Aspects 34-42, wherein releasably coupling the drug assembly to the vaporizer causes a temperature drop in a heating column of the vaporizer.

[0225] Aspect 44. The drug assembly of Aspect 43, wherein the temperature drop is measured by a temperature sensor in communication with the heating column.

[0226] Aspect 45. The drug assembly of any one of Aspects 34-44, wherein an interior of the drug assembly creates a seal with the vaporizer when the drug assembly is coupled to the vaporizer.

[0227] Aspect 46. The drug assembly of Aspect 45, wherein the drug cartridge includes a tapered base.

[0228] Aspect 47. The drug assembly of Aspect 46, wherein the tapered base has a 45 degree taper configured to improve thermal contact between the drug cartridge and the vaporizer and improve ease of detachment of the drug assembly from the vaporizer.

[0229] Aspect 48. The drug assembly of any one of Aspects 34-47, wherein the drug in the drug cartridge has a dose of about 1 mg to about 25 mg or about 0.5 mg to about 100 mg.

[0230] Aspect 49. The drug assembly of any one of Aspects 34-48, wherein a bottom surface of the drug cartridge is recessed within the housing.

[0231] Aspect 50. The drug assembly of any one of Aspects 34-49, wherein the safety cover is coupled to the housing such that when the holding chamber is coupled to the housing, the holding chamber provides a force to the safety cover to uncouple and / or detach the safety cover from the housing.56106261231.6Atty. Docket No. 119186-TBD

[0232] Aspect 51. A mouthpiece comprising: a body; and a plurality of engagement features extending from the body, wherein each of the plurality of engagement features includes a locking portion operable to engage with a corresponding projection of an receiving portion of a holding chamber; wherein the body forms a lumen operable to be in fluid communication with an aerosol containment portion of the holding chamber; wherein the body forms a plurality of atmospheric channels in communication with ambient air.

[0233] Aspect 52. The mouthpiece of Aspect 51 , further comprising an interior projection configured to contact a linkage arm of the holding chamber.

[0234] Aspect 53. The mouthpiece of Aspect 52, wherein the interior projection surrounds the lumen annularly.

[0235] Aspect 54. The mouthpiece of any one of Aspects 51-53, wherein the plurality of atmospheric channels numbers four and two of the four atmospheric channels are on an opposite side of the lumen from another two of the four atmospheric channels.

[0236] Aspect 55. The mouthpiece of any one of Aspects 51-54, wherein the mouthpiece includes a lip.

[0237] Aspect 56. The mouthpiece of Aspect 55, wherein the lip has an oval cross section.

[0238] Aspect 57. The mouthpiece of Aspect 56, wherein the oval cross section has a minor diameter of about 10 mm to about 20 mm.

[0239] Aspect 58. The mouthpiece of Aspect 57, wherein the oval cross section has a major diameter of about 30 mm to about 50 mm.

[0240] Aspect 59. A holding chamber comprising: a receiving portion, which forms a lumen; an aerosol containment portion coupled to the receiving portion and in fluid communication with the lumen; a plurality of projections operable to couple to one or more engagement features of a mouthpiece; and a valve operable to have an open state and closed state, wherein the open state allows aerosol in the aerosol containment portion to flow through the lumen; wherein the valve is in a normally closed state, wherein the valve is operable to be in an open position when a mouthpiece is compressed towards the receiving portion or when a drug assembly is coupled to the holding chamber.

[0241] Aspect 60. The holding chamber of Aspect 59, wherein the aerosol containment portion is operable to contain an aerosolized drug.57106261231.6Atty. Docket No. 119186-TBD

[0242] Aspect 61. The holding chamber of Aspect 59 or 60, wherein the receiving portion forms a plurality of finger grips.

[0243] Aspect 62. The holding chamber of Aspect 61 , wherein each of the plurality of projections extend from a respective one of the plurality of finger grips.

[0244] Aspect 63. The holding chamber of any one of Aspects 59-62, further comprising a linkage arm operable to be in contact with an interior projection of the mouthpiece.

[0245] Aspect 64. The holding chamber of Aspect 63, wherein the interior projection of the mouthpiece is operable to contact the linkage arm upon movement and / or translation or compression of the mouthpiece in a direction towards the receiving portion.

[0246] Aspect 65. The holding chamber of Aspect 63 or 64, wherein the one or more posts are operable to contact the linkage arm upon coupling of the holding chamber to the drug assembly housing.

[0247] Aspect 66. A vaporizer comprising: a drug assembly attachment port comprising an attachment mechanism operable to couple to a drug assembly; and a heating column operable to provide convective and conductive heating to the drug assembly, optionally wherein the vaporizer includes one or more openings for receiving at least one mating mechanism of a housing of a drug assembly.

[0248] Aspect 67. The vaporizer of Aspect 66, wherein the drug assembly attachment port comprises two or more openings extending to a groove, the two or more openings operable to receive a tab of two or more tabs of the drug assembly.

[0249] Aspect 68. The vaporizer of Aspect 67, wherein the groove is operable to receive the two or more tabs of the drug assembly.

[0250] Aspect 69. The vaporizer of Aspect 68, wherein the groove further includes two recesses, each recess operable to receive and lock a respective tab of the two or more tabs in place within the drug assembly attachment port.

[0251] Aspect 70. The vaporizer of any one of Aspects 66-69, further comprising a temperature sensor operable to measure a temperature of the heating column.

[0252] Aspect 71 . The vaporizer of Aspect 70, wherein the temperature sensor is operable to measure a temperature drop when the drug assembly is coupled to the drug assembly attachment port.58106261231.6Atty. Docket No. 119186-TBD

[0253] Aspect 72. The vaporizer of any one of Aspects 66-71 , wherein the heating column includes an upper tapered edge.

[0254] Aspect 73. The vaporizer of any one of Aspects 66-72, wherein the drug assembly includes a drug cartridge operable to hold a drug.

[0255] Aspect 74. The vaporizer of Aspect 73 when dependent on Aspect 72, wherein the drug cartridge includes a bottom tapered edge configured to interface with the upper tapered edge of the heating column.

[0256] Aspect 75. A method for coupling and / or operation of a mouthpiece in relation to a holding chamber containing an aerosolized drug, the method comprising: engaging a portion of the mouthpiece over a receiving portion of the holding chamber; rotating the mouthpiece such that two or more engagement features engage with a respective one of two or more finger grips of the holding chamber, thereby locking the mouthpiece in an installed configuration; and instructing a patient to press the mouthpiece in a direction towards the holding chamber, thereby opening a lumen formed in the holding chamber for inhalation of the aerosolized drug therethrough.

[0257] Aspect 76. The method of Aspect 75, the method further comprising instructing the patient to continue inhalation through a plurality of atmospheric channels of the mouthpiece.

[0258] Aspect 77. The method of Aspect 76, wherein the continued inhalation occurs after the aerosolized drug is completely evacuated from the holding chamber.

[0259] Aspect 78. The method of any one of Aspects 75-77, the method further comprising instructing the patient to discontinue the pressing on the mouthpiece, thereby moving a valve in communication with the lumen to an inactivated position and sealing the lumen.

[0260] Aspect 79. The method of Aspect 78, further comprising prior to the patient discontinuing the pressing, observing, via one or more indicators, that the aerosolized drug is completely evacuated from the holding chamber.

[0261] Aspect 80. The method of Aspect 79, wherein the one or more indicators include visual indicators.

[0262] Aspect 81. The method of Aspect 78, further comprising palpating the holding chamber to ensure that the aerosolized drug is completely evacuated.59106261231.6Atty. Docket No. 119186-TBD

[0263] Aspect 82. A drug for use as a medicament wherein the drug is administered to a patient in need thereof by the method of any of Aspects 1 to 33 or 75-81 .

[0264] Aspect 83. A drug for use in the treatment of a disease or disorder wherein the treatment comprises administering the drug to a patient in need thereof, wherein the drug is administered by the method defined in any of Aspects 1 to 33 or 75-81.

[0265] Aspect 84. A drug for use as a medicament wherein the drug is administered to a patient in need thereof by the drug assembly defined in any of Aspects 34-50.

[0266] Aspect 85. A drug for use in the treatment of a disease or disorder, wherein the treatment comprises administering the drug to a patient in need thereof, wherein the drug is administered as an aerosol formed with the drug assembly in any of Aspects 34-50.

[0267] Aspect 86. A drug for use as a medicament wherein the drug is administered to a patient in need thereof by the mouthpiece defined in any of Aspects 51-58.

[0268] Aspect 87. A drug for use in the treatment of a disease or disorder wherein the treatment comprises administering the drug to a patient in need thereof, wherein the drug is administered by the mouthpiece defined in any of Aspects 51 -58.

[0269] Aspect 88. A drug use as a medicament wherein the drug is administered to a patient in need thereof by the holding chamber defined in any of Aspects 59-65.

[0270] Aspect 89. A drug for use in the treatment of a disease or disorder wherein the treatment comprises administering the drug to a patient in need thereof, wherein the drug is administered by the holding chamber defined in any of Aspects 59-65.

[0271] Aspect 90. A drug for use as a medicament wherein the drug is an aerosolized drug formed by the vaporizer defined in any of Aspects 66-74.

[0272] Aspect 91. A drug for use in the treatment of a disease or disorder wherein the treatment comprises administering the drug to a patient in need thereof, wherein the drug is an aerosolized drug formed by the vaporizer defined in any of Aspects 66-74.

[0273] Aspect 92. A drug for use as a medicament wherein the drug to be administered to a patient is comprised within the drug assembly as defined in any of Aspects 34-50.

[0274] Aspect 93. A drug for use in the treatment of a disease or disorder wherein the drug is comprised within the drug assembly as defined in any of Aspects 34-50.

[0275] Aspect 94. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the disease or disorder is a mental disorder or nervous system disorder.60106261231.6Atty. Docket No. 119186-TBD

[0276] Aspect 95. The drug for use according to any of Aspects 82-94, wherein the drug comprises 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) or a pharmaceutical salt thereof, cannabinoid, tetrahydrocannabinol, entactogen 3,4- methylenedioxymethamphetamine, ketamine, lysergic acid diethylamide, psilocybin, N,N- dimethyltryptamine, mescaline, other phenylalkylamines, other tryptamines (e.g., a tryptamine other than 5-MeO-DMT and N,N-dimethyltryptamine), other ergolines, other serotonergic compounds, second generation psychedelics, nicotine, pentamidine, and / or opioids such as fentanyl, morphine, and / or naloxone.

[0277] Aspect 96. The drug for use according to any of Aspects 82-95, wherein the drug is 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) or a pharmaceutical salt thereof, cannabinoid, tetrahydrocannabinol, entactogen 3,4-methylenedioxymethamphetamine, ketamine, lysergic acid diethylamide, psilocybin, N,N-dimethyltryptamine, mescaline, other phenylalkylamines, other tryptamines (e.g., a tryptamine other than 5-MeO-DMT and N,N-dimethyltryptamine), other ergolines, other serotonergic compounds, second generation psychedelics, nicotine, pentamidine, and / or opioids such as fentanyl, morphine, and / or naloxone.

[0278] Aspect 97. The drug for use according to Aspect 96, wherein the second generation psychedelic is selected from the group consisting of novel tryptamines, for example, bretisilocin, or deuterated tryptamines and non-hallucinogenic psychoplastogens, optionally wherein the non-hallucinogenic psychoplastogens is tabernanthalog, / V-dimethylaminoisotryptamine or derivatives thereof.

[0279] Aspect 98. The drug for use according to Aspect 96, wherein the drug comprises 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) or a pharmaceutical salt thereof, preferably wherein the drug comprises 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) free base.

[0280] Aspect 99. The drug for use according to Aspect 97, wherein the drug is 5- Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) or a pharmaceutical salt thereof preferably, wherein the drug is 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) free base.

[0281] Aspect 100. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the disease or disorder is selected from the group consisting of postpartum61106261231.6Atty. Docket No. 119186-TBD depression, sleep disturbance, major depressive disorder, persistent depressive disorder, bipolar disorder, anxiety disorder, posttraumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorder, psychoactive substance abuse, insomnia, sleep apnea, alcohol use disorder, suicidal ideation, psychoactive substance use disorder, opioid abuse.

[0282] Aspect 101. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the disease or disorder is selected from the group consisting of postpartum depression, sleep disturbance, major depressive disorder, persistent depressive disorder, bipolar disorder, anxiety disorder, posttraumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorder and psychoactive substance abuse.

[0283] Aspect 102. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug comprises 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) or a pharmaceutical salt thereof and the disease or disorder is selected from the group consisting of postpartum depression, sleep disturbance, major depressive disorder, persistent depressive disorder, bipolar disorder, anxiety disorder, posttraumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorder and psychoactive substance abuse.

[0284] Aspect 103. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug is 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) or a pharmaceutical salt thereof and the disease or disorder is selected from the group consisting of postpartum depression, sleep disturbance, major depressive disorder, persistent depressive disorder, bipolar disorder, anxiety disorder, posttraumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorder and psychoactive substance abuse.

[0285] Aspect 104. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , 93, or 102, wherein the drug comprises 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) or a pharmaceutical salt thereof and the disease or disorder is major depressive disorder.

[0286] Aspect 105. The drug for use according to Aspect 103, wherein the drug is 5- Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) or a pharmaceutical salt thereof and the disease or disorder is major depressive disorder.62106261231.6Atty. Docket No. 119186-TBD

[0287] Aspect 106. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug comprises a cannabinoid.

[0288] Aspect 107. The drug for use according any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug is a cannabinoid.

[0289] Aspect 108. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug comprises a tetrahydrocannabinol.

[0290] Aspect 109. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug is a tetrahydrocannabinol.

[0291] Aspect 110. The drug for use according to any of Aspects 82, 84, 86, 88, 90, or92, wherein the drug comprises entactogen 3,4-methylenedioxymethamphetamine.

[0292] Aspect 111. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or93, wherein the drug is entactogen 3,4-methylenedioxymethamphetamine.

[0293] Aspect 112. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug comprises ketamine.

[0294] Aspect 113. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug is ketamine.

[0295] Aspect 114. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug comprises lysergic acid diethylamide.

[0296] Aspect 115. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug is lysergic acid diethylamide.

[0297] Aspect 116. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug comprises psilocybin.

[0298] Aspect 117. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug is psilocybin.

[0299] Aspect 118. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug comprises N,N-dimethyltryptamine.

[0300] Aspect 119. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug is N,N-dimethyltryptamine.

[0301] Aspect 120. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug comprises mescaline or other phenylalkylamines.63106261231.6Atty. Docket No. 119186-TBD

[0302] Aspect 121. The drug for use according any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug is mescaline or other phenylalkylamines.

[0303] Aspect 122. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug comprises a tryptamine other than 5-MeO-DMT, psilocybin or N,N- dimethyltryptamine.

[0304] Aspect 123. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug is a tryptamine other than 5-MeO-DMT, psilocybin or N,N- dimethyltryptamine.

[0305] Aspect 124. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug comprises an ergoline other than lysergic acid diethylamide (LSD).

[0306] Aspect 125. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug is an ergoline other than lysergic acid diethylamide (LSD).

[0307] Aspect 126. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug comprises a serotonergic compound.

[0308] Aspect 127. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug is a serotonergic compound.

[0309] Aspect 128. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug comprises nicotine.

[0310] Aspect 129. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug is nicotine.

[0311] Aspect 130. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug comprises pentamidine.

[0312] Aspect 131. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug is pentamidine.

[0313] Aspect 132. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug comprises fentanyl, morphine, and / or naloxone.

[0314] Aspect 133. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug is fentanyl, morphine, and / or naloxone.

[0315] Aspect 134. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug comprises a second generation psychedelic.64106261231.6Atty. Docket No. 119186-TBD

[0316] Aspect 135. The drug for use according to any of Aspects 83, 85, 87, 89, 91 , or 93, wherein the drug is a second generation psychedelic.

[0317] Aspect 136. A method for coupling and / or operation of a mouthpiece in relation to a holding chamber containing an aerosolized drug, the method comprising installing a portion of the mouthpiece over a receiving portion of the holding chamber; rotating the mouthpiece in a direction to allow two or more engagement features to engage with a respective one of two or more finger grips of the holding chamber; and locking, when a locking portion of the two or more engagement features extends past the respective one of the two or more finger grips, the mouthpiece in an installed configuration.

[0318] Aspect 137. The method of Aspect 136, wherein the installed configuration prevents rotational displacement of the mouthpiece in relation to the holding chamber.

[0319] Aspect 138. The method of Aspect 136 or 137, wherein the installed configuration allows linear displacement of the mouthpiece in relation to the holding chamber.

[0320] Aspect 139. The method of any one of Aspects 136-138, the method further comprising pressing the mouthpiece in a direction towards the holding chamber; and opening, when the mouthpiece is moved to an activated position by the pressing, a lumen formed in the aerosol containment portion for inhalation of the aerosolized drug therethrough.

[0321] Aspect 140. The method of Aspect 139, the method further comprising allowing continued inhalation through a plurality of atmospheric channels of the mouthpiece.

[0322] Aspect 141. The method of Aspect 139 or 140, the method further comprising discontinuing the pressing on the mouthpiece, thereby moving a valve in communication with the lumen to an inactivated position and sealing the lumen.

[0323] Aspect 142. A method for administration of a drug to a patient in need thereof, the method comprising: vaporizing a drug into an aerosol containment device coupled to a vaporizer; removing the aerosol containment device from the vaporizer; installing a portion of a mouthpiece over a receiving portion of the aerosol containment device; and opening a lumen in the aerosol containment device, wherein opening the lumen provides fluid communication between the aerosol containment device and the mouthpiece for inhalation therethrough.65106261231.6Atty. Docket No. 119186-TBD

[0324] Aspect 143. The method of aspect 142, wherein the installation of the mouthpiece over the receiving portion of the aerosol containment device prevents unintended actuation of a valve in the aerosol containment device.

[0325] Aspect 145. The method of Aspect 142 or 143, wherein installing the portion of the mouthpiece over the receiving portion of the aerosol containment device includes a two- step attachment process.

[0326] Aspect 146. The method of Aspect 145, wherein the two-step attachment process includes inserting the mouthpiece into a portion of the receiving portion; and rotating the mouthpiece in a direction to allow two or more engagement features to engage with a respective one of two or more finger grips of the aerosol containment device; wherein the rotating causes the mouthpiece to lock in an installed configuration when a locking portion of the two or more engagement features extends past the respective one of the two or more finger grips.

[0327] Aspect 147. The method of Aspect 145 or 146, wherein linear motion of the mouthpiece with respect to the aerosol containment device is prevented until the two-step attachment process is completed.

[0328] Aspect 148. The method of any one of Aspects 142-147, wherein opening the lumen in the mouthpiece includes pressing the mouthpiece in a direction towards the aerosol containment device, wherein the pressing actuates a valve in fluid communication with the lumen to an open state.

[0329] Aspect 149. The method of any one of Aspects 142-148, the method further comprising facilitating continued inhalation via a plurality of atmospheric channels.

[0330] Aspect 150. The method of any one of Aspects 142-149, the method further comprising sealing the lumen when inhalation is completed.

[0331] Aspect 151. The method of any one of Aspects 142-150, the method further comprising: coupling the aerosol containment device to a drug assembly containing a drug; and coupling the drug assembly and the aerosol containment device to the vaporizer, prior to vaporizing the drug into the aerosol containment device.

[0332] Aspect 152. The method of Aspect 151 , wherein coupling the aerosol containment device to the drug assembly releases a safety cover from the drug assembly.66106261231.6Atty. Docket No. 119186-TBD

[0333] Aspect 153. The method of Aspect 151 or 162, wherein coupling the drug assembly and the aerosol containment device to the vaporizer comprises: inserting two or more attachment features into a groove of the vaporizer; and rotating the drug assembly and aerosol containment device until the two or more attachment features lock into a respective one of two or more recesses of the vaporizer.

[0334] Aspect 154. The method of Aspect 153, wherein removing the aerosol containment device from the vaporizer comprises removing the aerosol containment device from the drug assembly.

[0335] Aspect 155. The method of Aspect 154, wherein the drug assembly remains coupled to the vaporizer after the aerosol containment device is removed from the vaporizer.

[0336] Aspect 156. The method of any one of Aspects 146-155, wherein the installed configuration prevents rotational movement of the mouthpiece in relation to the aerosol containment device.

[0337] Aspect 157. The method of any one of Aspects 146-156, wherein pressing the mouthpiece in the direction towards the aerosol containment device includes linearly translating the mouthpiece along the two or more finger grips.

[0338] Aspect 158. The method of any one of Aspects 146-157, wherein opening the lumen comprises actuating a valve of the aerosol containment device by pressing the mouthpiece in the direction towards the aerosol containment device.

[0339] Aspect 159. A drug assembly configured to contain a drug, the drug assembly comprising: a drug cartridge; a housing operable to contain the drug cartridge and releasably couple to a holding chamber and / or a vaporizer, the housing comprising at least one mating mechanism; and a safety cover releasably coupled to the housing, wherein the safety cover is coupled to the housing prior to filling the drug cartridge with the drug, wherein the safety cover detaches from the drug cartridge when the housing is releasably coupled to the holding chamber.

[0340] Aspect 160. The drug assembly of Aspect 159, wherein the drug assembly is prevented from being uncoupled from the vaporizer until the holding chamber is uncoupled from the drug assembly.67106261231.6Atty. Docket No. 119186-TBD

[0341] Aspect 161. The drug assembly of Aspect 159 or 160, wherein the at least one mating mechanism comprises a first mating mechanism and a second mating mechanism, the first mating mechanism and the second mating mechanism operable to releasably couple to two or more corresponding mating mechanisms of the holding chamber.

[0342] Aspect 162. The drug assembly of Aspect 161 , wherein the first mating mechanism and the second mating mechanism comprise ledges operable to receive the two or more corresponding mating mechanisms of the holding chamber.

[0343] Aspect 163. The drug assembly of Aspect 161 or 162, wherein the at least one mating mechanism further comprises a third mating mechanism and a fourth mating mechanism, the third mating mechanism and the fourth mating mechanism operable to releasably couple to a groove of the vaporizer.

[0344] Aspect 164. The drug assembly of Aspect 163, wherein the third mating mechanism and the fourth mating mechanism comprise tabs operable to slide along the groove of the vaporizer and lock into place in corresponding recesses of the groove of the vaporizer.

[0345] Aspect 165. The drug assembly of any one of Aspects 159-164, wherein releasably coupling the drug assembly to the vaporizer causes a temperature drop in a heating column of the vaporizer.

[0346] Aspect 166. The drug assembly of any one of Aspects 159-165, wherein an interior of the drug assembly creates a seal with the vaporizer when the drug assembly is coupled to the vaporizer.

[0347] Aspect 167. The drug assembly of Aspect 166, wherein the drug cartridge includes a tapered base.

[0348] Aspect 168. The drug assembly of Aspect 167, wherein the tapered base has a 45 degree taper configured to improve thermal contact between the drug cartridge and the vaporizer and improve ease of detachment of the drug assembly from the vaporizer.

[0349] Aspect 169. The drug assembly of any one of Aspects 159-168, wherein the drug in the drug cartridge has a dose of about 1 mg to about 25 mg or about 0.5 mg to about 100 mg.68106261231.6Atty. Docket No. 119186-TBD

[0350] Aspect 170. A mouthpiece comprising: a body; and a plurality of engagement features extending from the body, wherein each of the plurality of engagement features includes a locking portion operable to engage with a corresponding projection of an interface portion of a holding chamber; wherein the body forms a lumen operable to be in fluid communication with an aerosol containment area of the holding chamber; wherein the body forms a plurality of atmospheric channels in communication with ambient air.

[0351] Aspect 171. The mouthpiece of Aspect 170, further comprising an interior projection configured to contact a linkage arm of the holding chamber.

[0352] Aspect 172. The mouthpiece of Aspect 171 , wherein the interior projection surrounds the lumen annularly.

[0353] Aspect 173. The mouthpiece of any one of Aspects 170-172, wherein the plurality of atmospheric channels numbers four and two of the four atmospheric channels are on an opposite side of the lumen from another two of the four atmospheric channels.

[0354] Aspect 174. A holding chamber comprising: an interface portion, which forms a lumen; an aerosol containment portion coupled to the interface portion and in fluid communication with the lumen; a plurality of projections operable to couple to one or more engagement features of a mouthpiece; and a valve operable to have an open state and closed state, wherein the open state allows aerosol in the aerosol containment portion to flow through the lumen; wherein the valve is in a normally closed state, wherein the valve is operable to be in an open position when a mouthpiece is compressed towards the interface portion.

[0355] Aspect 175. The holding chamber of Aspect 174, wherein the interface portion forms a plurality of finger grips.

[0356] Aspect 176. The holding chamber of Aspect 175, wherein each of the plurality of projections extend from a respective one of the plurality of finger grips.

[0357] Aspect 177. The holding chamber of Aspect 176, further comprising a linkage arm operable to be in contact with an interior projection of the mouthpiece.

[0358] Aspect 178. The holding chamber of Aspect 177, wherein the interior projection is operable to contact the linkage arm upon movement of the mouthpiece in a direction towards the interface portion.69106261231.6Atty. Docket No. 119186-TBD

[0359] Aspect 179. A drug for use as a medicament wherein the drug is administered to a patient in need thereof by the method of any of Aspects 136-158.

[0360] Aspect 180. A drug for use in the treatment of a disease or disorder wherein the treatment comprises administering the drug to a patient in need thereof, wherein the drug is administered by the method defined in any of Aspects 136-158.

[0361] Aspect 181. A drug for use as a medicament wherein the drug is administered to a patient in need thereof by the drug assembly defined in any of Aspects 159-169.

[0362] Aspect 182. A drug for use in the treatment of a disease or disorder wherein the treatment comprises administering the drug to a patient in need thereof, wherein the drug is administered by the mouthpiece defined in any of Aspects 140-173.

[0363] Aspect 183. A drug for use as a medicament wherein the drug is administered to a patient in need thereof by the holding chamber defined in Aspects 174-178.

[0364] Aspect 184. A drug for use in the treatment of a disease or disorder wherein the drug is comprised within the drug assembly as defined in any of Aspects 159-169 or 45.

[0365] Aspect 185. The drug for use according to any of Aspects 179-184, wherein the disease or disorder is a mental disorder or nervous system disorder.

[0366] Aspect 186. The drug for use according to any of Aspects 179-185, wherein the drug comprises 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) or a pharmaceutical salt thereof, cannabinoid, tetrahydrocannabinol, entactogen 3,4- methylenedioxymethamphetamine, ketamine, lysergic acid diethylamide, psilocybin, N,N- dimethyltryptamine, phenylalkylamine mescaline, other tryptamines (e.g., a tryptamine other than 5-MeO-DMT and N,N-dimethyltryptamine), other ergolines, other serotonergic compounds, second generation psychedelics, nicotine, pentamidine, and / or opioids such as fentanyl, morphine, and / or naloxone.

[0367] Aspect 187. The drug for use according to any of Aspects 179-185, wherein the drug is 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) or a pharmaceutical salt thereof, cannabinoid, tetrahydrocannabinol, entactogen 3,4- methylenedioxymethamphetamine, ketamine, lysergic acid diethylamide, psilocybin, N,N- dimethyltryptamine, phenylalkylamine mescaline, other tryptamines (e.g., a tryptamine other than 5-MeO-DMT and N,N-dimethyltryptamine), other ergolines, other serotonergic70106261231.6Atty. Docket No. 119186-TBD compounds, second generation psychedelics, nicotine, pentamidine, and / or opioids such as fentanyl, morphine, and / or naloxone.

[0368] Aspect 188. The drug for use according to Aspect 187, wherein the second generation psychedelic is selected from the group consisting of deuterated tryptamines and non-hallucinogenic psychoplastogens, optionally wherein the non-hallucinogenic psychoplastogens is tabernanthalog, / V-dimethylaminoisotryptamine or derivatives thereof.

[0369] Aspect 189. The drug for use according to Aspect 187, wherein the drug comprises 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) or a pharmaceutical salt thereof, preferably wherein the drug comprises 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) free base.

[0370] Aspect 190. The drug for use according to Aspect 188, wherein the drug is 5- Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) or a pharmaceutical salt thereof preferably, wherein the drug is 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) free base.

[0371] Aspect 191. The drug for use according to any of Aspects 180, 182, 184 or 186 to 189, wherein the disease or disorder is selected from the group consisting of postpartum depression, sleep disturbance, major depressive disorder, persistent depressive disorder, bipolar disorder, anxiety disorder, posttraumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorder, psychoactive substance abuse, epilepsy, sickness associated with chemotherapy, acute pain, chronic pain, phantom pain, migraine, multiple sclerosis, multiple sclerosis spasms, schizophrenia, insomnia, rheumatoid arthritis, psychosis, HIV-induced anorexia, sleep apnea, alcohol use disorder, suicidal ideation, psychoactive substance use disorder, smoking cessation, Parkinson’s disease, dementia, pleuropneumonitis, parasitic conditions, pneumocystis pneumonia, HIV related dementia, cough, diarrhoea, nausea, opioid abuse, seizures and shortness of breath.

[0372] Aspect 192. The drug for use according to Aspects 185 or 1995, wherein the disease or disorder is selected from the group consisting of postpartum depression, sleep disturbance, major depressive disorder, persistent depressive disorder, bipolar disorder,71106261231.6Atty. Docket No. 119186-TBD anxiety disorder, posttraumatic stress disorder, body dysmorphic disorder, obsessive- compulsive disorder, eating disorder and psychoactive substance abuse.

[0373] Aspect 193. The drug for use according to any of Aspects 180, 182, 184, 186, 189 or 191 , wherein the drug comprises 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) or a pharmaceutical salt thereof and the disease or disorder is selected from the group consisting of postpartum depression, sleep disturbance, major depressive disorder, persistent depressive disorder, bipolar disorder, anxiety disorder, posttraumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorder and psychoactive substance abuse.

[0374] Aspect 194. The drug for use according to any of Aspects 180, 182, 184, 187, 190 or 191 , wherein the drug is 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) or a pharmaceutical salt thereof and the disease or disorder is selected from the group consisting of postpartum depression, sleep disturbance, major depressive disorder, persistent depressive disorder, bipolar disorder, anxiety disorder, posttraumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorder and psychoactive substance abuse.

[0375] Aspect 195. The drug for use according to Aspect 193, wherein the drug comprises 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) or a pharmaceutical salt thereof and the disease or disorder is major depressive disorder.

[0376] Aspect 196. The drug for use according to Aspect 58, wherein the drug is 5- Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) or a pharmaceutical salt thereof and the disease or disorder is major depressive disorder.

[0377] Aspect 197. The drug for use according to any of Aspects 180, 182, 184, 186 or 191 , wherein the drug comprises a cannabinoid and the disease or disorder is selected from the group consisting of epilepsy, sickness associated with chemotherapy, chronic pain, multiple sclerosis spasms, anxiety disorder, posttraumatic stress disorder, major depressive disorder, bipolar disorder, schizophrenia and insomnia.

[0378] Aspect 198. The drug for use according any of Aspects 180, 182, 184, 187 or 191 , wherein the drug is a cannabinoid, and the disease or disorder is selected from the group consisting of epilepsy, sickness associated with chemotherapy, chronic pain, multiple72106261231.6Atty. Docket No. 119186-TBD sclerosis spasms, anxiety disorder, posttraumatic stress disorder, major depressive disorder, bipolar disorder, schizophrenia and insomnia.

[0379] Aspect 199. The drug for use according to any of Aspects 180, 182, 184, 186 or 191 , wherein the drug comprises a tetrahydrocannabinol and the disease or disorder is selected from the group consisting of HIV-induced anorexia, sickness associated with chemotherapy, chronic pain, sleep apnea and multiple sclerosis.

[0380] Aspect 200. The drug for use according to any of Aspects 180, 182, 184, 187 or 191 , wherein the drug is a tetrahydrocannabinol, and the disease or disorder is selected from the group consisting of HIV-induced anorexia, sickness associated with chemotherapy, chronic pain, sleep apnea and multiple sclerosis.

[0381] Aspect 201. The drug for use according to any of Aspects 180, 182, 184, 186 or 191 , wherein the drug comprises entactogen 3,4-methylenedioxymethamphetamine and the disease or disorder is selected from the group consisting of posttraumatic stress disorder, major depressive disorder and alcohol use disorder.

[0382] Aspect 202. The drug for use according to any of Aspects 180, 182, 184, 187 or 191 , wherein the drug is entactogen 3,4-methylenedioxymethamphetamine and the disease or disorder is selected from the group consisting of posttraumatic stress disorder, major depressive disorder and alcohol use disorder.

[0383] Aspect 203. The drug for use according to any of Aspects 180, 182, 184, 186 or 191 , wherein the drug comprises ketamine and the disease or disorder is selected from the group consisting of acute pain, nausea, suicidal ideation, psychoactive substance use disorder and posttraumatic stress disorder.

[0384] Aspect 204. The drug for use according to any of Aspects 180, 182, 184, 187 or 191 , wherein the drug is ketamine, and the disease or disorder is selected from the group consisting of acute pain, nausea, suicidal ideation, drug addiction and posttraumatic stress disorder.

[0385] Aspect 205. The drug for use according to any of Aspects 180, 182, 184, 186 or 191 , wherein the drug comprises lysergic acid diethylamide and the disease or disorder is selected from the group consisting of alcohol use disorder, anxiety disorder, psychoactive substance use disorder, and phantom pain.73106261231.6Atty. Docket No. 119186-TBD

[0386] Aspect 206. The drug for use according to any of Aspects 180, 182, 184, 187 or 191 , wherein the drug is lysergic acid diethylamide, and the disease or disorder is selected from the group consisting of alcohol use disorder, anxiety disorder, psychoactive substance use disorder, and phantom pain.

[0387] Aspect 207. The drug for use according to any of Aspects 180, 182, 184, 186 or 191 , wherein the drug comprises psilocybin and the disease or disorder is selected from the group consisting of anxiety disorder, psychoactive substance use disorder, smoking cessation, obsessive-compulsive disorder, psychosis, posttraumatic stress disorder and migraine.

[0388] Aspect 208. The drug for use according to any of Aspects 180, 182, 184, 187 or 191 , wherein the drug is psilocybin, and the disease or disorder is selected from the group consisting of anxiety disorder, psychoactive substance use disorder, smoking cessation, obsessive-compulsive disorder, psychosis, posttraumatic stress disorder and migraine.

[0389] Aspect 209. The drug for use according to any of Aspects 180, 182, 184, 186 or 191 , wherein the drug comprises N,N-dimethyltryptamine and the disease or disorder is selected from the group consisting of postpartum depression, sleep disturbance, major depressive disorder, persistent depressive disorder, bipolar disorder, anxiety disorder, posttraumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorder, psychoactive substance abuse and Parkinson’s disease.

[0390] Aspect 210. The drug for use according to any of Aspects 180, 182, 184, 187 or 191 , wherein the drug is N,N-dimethyltryptamine and the disease or disorder is selected from the group consisting of postpartum depression, sleep disturbance, major depressive disorder, persistent depressive disorder, bipolar disorder, anxiety disorder, posttraumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorder, psychoactive substance abuse and Parkinson’s disease.

[0391] Aspect 211. The drug for use according to any of Aspects 180, 182, 184, 186 or 191 , wherein the drug comprises phenylalkylamine mescaline and the disease or disorder is selected from the group consisting of alcohol use disorder, psychoactive substance use disorder, posttraumatic stress disorder and anxiety disorder.

[0392] Aspect 212. The drug for use according any of Aspects 180, 182, 184, 187 or 191 , wherein the drug is phenylalkylamine mescaline and the disease or disorder is selected74106261231.6Atty. Docket No. 119186-TBD from the group consisting of alcohol use disorder, psychoactive substance use disorder, posttraumatic stress disorder and anxiety disorder.

[0393] Aspect 213. The drug for use according to any of Aspects 180, 182, 184, 186 or 191 , wherein the drug comprises a tryptamine other than 5-MeO-DMT, psilocybin or N,N- dimethyltryptamine and the disease or disorder is selected from the group consisting of anxiety disorder, schizophrenia, bipolar disorder, psychoactive substance use disorder and chronic pain.

[0394] Aspect 214. The drug for use according to any of Aspects 180, 182, 184, 187 or 191 , wherein the drug is a tryptamine other than 5-MeO-DMT, psilocybin or N,N- dimethyltryptamine and the disease or disorder is selected from the group consisting of anxiety disorder, schizophrenia, bipolar disorder, psychoactive substance use disorder and chronic pain.

[0395] Aspect 215. The drug for use according to any of Aspects 180, 182, 184, 186 or 191 , wherein the drug comprises an ergoline other than lysergic acid diethylamide (LSD) and the disease or disorder is selected from the group consisting of migraine, Parkinson’s disease, and dementia.

[0396] Aspect 216. The drug for use according to any of Aspects 180, 182, 184, 187 or 191 , wherein the drug is an ergoline other than lysergic acid diethylamide (LSD) and the disease or disorder is selected from the group consisting of migraine, Parkinson’s disease, and dementia.

[0397] Aspect 217. The drug for use according to any of Aspects 180, 182, 184, 186 or 191 , wherein the drug comprises a serotonergic compound and the disease or disorder is selected from the group consisting of anxiety disorder, obsessive-compulsive disorder, eating disorder, chronic pain and posttraumatic stress disorder.

[0398] Aspect 218. The drug for use according to any of Aspects 180, 182, 184, 187 or 191 , wherein the drug is a serotonergic compound, and the disease or disorder is selected from the group consisting of anxiety disorder, obsessive-compulsive disorder, eating disorder, chronic pain and posttraumatic stress disorder.

[0399] Aspect 219. The drug for use according to any of Aspects 180, 182, 184, 186 or 191 , wherein the drug comprises nicotine and the disease or disorder is selected from the75106261231.6Atty. Docket No. 119186-TBD group consisting of smoking cessation, Parkinson’s disease, dementia and preferably Parkinson’s disease and dementia.

[0400] Aspect 220. The drug for use according to any of Aspects 180, 182, 184, 187 or 191 , wherein the drug is nicotine, and the disease or disorder is selected from the group consisting of smoking cessation, Parkinson’s disease and dementia, preferably Parkinson’s disease and dementia.

[0401] Aspect 221. The drug for use according to any of Aspects 180, 182, 184, 186 or 191 , wherein the drug comprises pentamidine and the disease or disorder is selected from the group consisting of parasitic conditions, pneumocystis pneumonia and HIV related dementia.

[0402] Aspect 222. The drug for use according to any of Aspects 180, 182, 184, 187 or 191 , wherein the drug is pentamidine and the disease or disorder is selected from the group consisting of parasitic conditions, pneumocystis pneumonia and HIV related dementia.

[0403] Aspect 223. The drug for use according to Aspect 221 or 222, wherein the parasitic condition is selected from the group consisting of African trypanosomiasis, leishmaniasis and Balamuthia.

[0404] Aspect 224. The drug for use according to any of Aspects 180, 182, 184, 186 or 191 , wherein the drug comprises fentanyl, morphine, and / or naloxone and the disease or disorder is selected from the group consisting of acute pain, chronic pain, shortness of breath, opioid abuse, cough and diarrhea.

[0405] Aspect 225. The drug for use according to any of Aspects 180, 182, 184, 187 or 191 , wherein the drug is fentanyl, morphine, and / or naloxone and the disease or disorder is selected from the group consisting of acute pain, chronic pain, shortness of breath, opioid abuse, cough and diarrhea.

[0406] Aspect 226. The drug for use according to any of Aspects 180, 182, 184, 186 or 191 , wherein the drug comprises a second generation psychedelic, and the disease or disorder is selected from the group consisting of postpartum depression, sleep disturbance, major depressive disorder, persistent depressive disorder, bipolar disorder, anxiety disorder, posttraumatic stress disorder, body dysmorphic disorder, obsessive- compulsive disorder, eating disorder and psychoactive substance abuse.76106261231.6Atty. Docket No. 119186-TBD

[0407] Aspect 227. The drug for use according to any of Aspects 180, 182, 184, 187 or 191 , wherein the drug is a second generation psychedelic, and the disease or disorder is selected from the group consisting of postpartum depression, sleep disturbance, major depressive disorder, persistent depressive disorder, bipolar disorder, anxiety disorder, posttraumatic stress disorder, body dysmorphic disorder, obsessive-compulsive disorder, eating disorder and psychoactive substance abuse.

[0408] Although a variety of information was used to explain aspects within the scope of the appended claims, no limitation of the claims should be implied based on particular features or arrangements, as one of ordinary skill would be able to derive a wide variety of implementations. Further and although some subject matter may have been described in language specific to structural features and / or method steps, it is to be understood that the subject matter defined in the appended claims is not necessarily limited to these described features or acts. Such functionality can be distributed differently or performed in components other than those identified herein. Rather, the described features and steps are disclosed as possible components of systems and methods within the scope of the appended claims.77106261231.6

Claims

Atty. Docket No. 119186-TBDCLAIMSWhat is claimed is:

1. A method for coupling and / or operation of a mouthpiece in relation to a holding chamber containing an aerosolized drug, the method comprising: engaging a portion of the mouthpiece over a receiving portion of the holding chamber; rotating the mouthpiece in a direction to allow two or more engagement features to engage with a respective one of two or more finger grips of the holding chamber; and locking, when a locking portion of the two or more engagement features extends past the respective one of the two or more finger grips, the mouthpiece in an installed configuration.

2. The method of claim 1 , wherein the installed configuration prevents rotational displacement of the mouthpiece in relation to the holding chamber.

3. The method of claim 1 , wherein the installed configuration allows linear displacement of the mouthpiece in relation to the holding chamber.

4. The method of claim 1 , the method further comprising: instructing a patient to press the mouthpiece in a direction towards the holding chamber, thereby opening, when the mouthpiece is moved to an activated position by the pressing, a lumen formed in the holding chamber for inhalation of the aerosolized drug therethrough.

5. The method of claim 4, the method further comprising instructing the patient to continue inhaling through a plurality of atmospheric channels of the mouthpiece.

6. The method of claim 4, the method further comprising discontinuing the pressing on the mouthpiece, thereby moving a valve in communication with the lumen to an inactivated position and sealing the lumen.78106261231.6Atty. Docket No. 119186-TBD7. The method of claim 4, wherein pressing the mouthpiece towards the holding chamber moves a valve in communication with the lumen to an activated position, thereby unsealing the lumen.

8. A method for administration of a drug to a patient in need thereof, the method comprising: vaporizing a drug into a holding chamber coupled to a vaporizer; removing the holding chamber from the vaporizer; and coupling a portion of a mouthpiece to a receiving portion of the holding chamber.

9. The method of claim 8, further comprising instructing a patient to open a lumen in the holding chamber.

10. The method of claim 9, wherein opening the lumen provides fluid communication between the holding chamber and the mouthpiece for inhalation therethrough.

11. The method of claim 8, wherein the coupling of the mouthpiece to the receiving portion of the holding chamber prevents unintended actuation of a valve in the holding chamber.

12. The method of claim 8, wherein coupling the portion of the mouthpiece to the receiving portion of the holding chamber includes a two-step attachment process.

13. The method of claim 12, wherein the two-step attachment process includes: engaging the mouthpiece with a portion of the receiving portion of the holding chamber; and rotating the mouthpiece in a direction to allow two or more engagement features to engage with a respective one of two or more finger grips of the holding chamber;79106261231.6Atty. Docket No. 119186-TBD wherein the rotating causes the mouthpiece to lock in an installed configuration when a locking portion of the two or more engagement features extends past the respective one of the two or more finger grips.

14. The method of claim 13, wherein engaging the mouthpiece with a portion of the receiving portion of the holding chamber includes inserting the mouthpiece into a portion of the receiving portion of the holding chamber.

15. The method of claim 12, wherein linear motion of the mouthpiece with respect to the holding chamber is restricted until the two-step attachment process is completed.

16. The method of claim 9, wherein instructing the patient to open the lumen includes instructing the patient to press the mouthpiece in a direction towards the holding chamber, wherein the pressing actuates a valve in fluid communication with the lumen to an open state.

17. The method of claim 10, the method further comprising: instructing the patient to continue inhalation via a plurality of atmospheric channels.

18. The method of claim 10, the method further comprising instructing the patient to seal the lumen when inhalation is completed.

19. The method of claim 8, the method further comprising: coupling the holding chamber to a drug assembly containing the drug; and coupling the drug assembly and the holding chamber to the vaporizer, prior to vaporizing the drug into the holding chamber.

20. The method of claim 8, the method further comprising: coupling the holding chamber to a drug assembly containing the drug; and subsequent to coupling the holding chamber to the drug assembly, coupling the holding chamber and the drug assembly to the vaporizer.80106261231.6Atty. Docket No. 119186-TBD21. The method of claim 19, wherein coupling the holding chamber to the drug assembly releases a safety cover from the drug assembly.

22. The method of claim 21 , wherein the safety cover prevents attachment of the drug assembly to the vaporizer until the safety cover is removed.

23. The method of claim 19, wherein coupling the drug assembly and the holding chamber to the vaporizer comprises: inserting two or more attachment features into a groove of the vaporizer; and rotating the drug assembly and the holding chamber until the two or more attachment features lock into a respective one of two or more recesses of the vaporizer.

24. The method of claim 19, wherein removing the holding chamber from the vaporizer comprises removing the holding chamber from the drug assembly.

25. The method of claim 24, wherein the drug assembly remains coupled to the vaporizer after the holding chamber is removed from the vaporizer.

26. The method of claim 19, wherein the vaporizer is heated to a vaporization temperature prior to coupling the drug assembly and the holding chamber to the vaporizer.

27. The method of claim 26, wherein the holding chamber is coupled to the drug assembly prior to heating the vaporizer to the vaporization temperature.

28. The method of claim 23, wherein coupling the drug assembly to the vaporizer causes a temperature drop within the vaporizer.

29. The method of claim 28, wherein the temperature drop occurs on or within a heating column of the vaporizer.

30. The method of claim 28, wherein the temperature drop indicates that the drug assembly is properly coupled to the vaporizer.81106261231.6Atty. Docket No. 119186-TBD31. The method of claim 13, wherein the installed configuration prevents rotational movement of the mouthpiece in relation to the holding chamber.

32. The method of claim 13, wherein pressing the mouthpiece in a direction towards the holding chamber includes linearly translating the mouthpiece along the two or more finger grips.

33. The method of claim 9, wherein opening the lumen comprises actuating a valve of the holding chamber by pressing the mouthpiece in a direction towards the holding chamber.

34. A drug assembly configured to contain a drug, the drug assembly comprising: a drug cartridge; a housing operable to contain the drug cartridge and releasably couple to a holding chamber and / or a vaporizer, the housing comprising at least one mating mechanism; and a safety cover releasably coupled to the housing, wherein the safety cover detaches from the housing when the housing is releasably coupled to the holding chamber.

35. The drug assembly of claim 34, wherein the safety cover is coupled to the housing prior to filling the drug cartridge with the drug.

36. The drug assembly of claim 34, wherein the drug assembly is prevented from being uncoupled from the vaporizer until the holding chamber is uncoupled from the drug assembly.

37. The drug assembly of claim 34, wherein the safety cover prevents attachment of the drug assembly to the vaporizer until the safety cover is removed from the housing.

38. The drug assembly of claim 34, wherein the at least one mating mechanism comprises a first mating mechanism and a second mating mechanism, the first mating82106261231.6Atty. Docket No. 119186-TBD mechanism and the second mating mechanism operable to releasably couple to two or more corresponding mating mechanisms of the holding chamber.

39. The drug assembly of claim 38, wherein the first mating mechanism and the second mating mechanism comprise ledges operable to receive the two or more corresponding mating mechanisms of the holding chamber.

40. The drug assembly of claim 38, wherein the at least one mating mechanism further comprises a third mating mechanism and a fourth mating mechanism, the third mating mechanism and the fourth mating mechanism operable to releasably couple to a groove of the vaporizer.41 . The drug assembly of claim 40, wherein the third mating mechanism and the fourth mating mechanism comprise tabs operable to slide along the groove of the vaporizer and lock into place in corresponding recesses of the groove of the vaporizer.

42. The drug assembly of claim 34, wherein the drug assembly is configured to be coupled to the vaporizer after a heating column of the vaporizer is preheated to a vaporization temperature.

43. The drug assembly of claim 42, wherein releasably coupling the drug assembly to the vaporizer causes a temperature drop in the heating column of the vaporizer.

44. The drug assembly of claim 43, wherein the temperature drop is measured by a temperature sensor in communication with the heating column.

45. The drug assembly of claim 34, wherein an interior of the drug assembly creates a seal with the vaporizer when the drug assembly is coupled to the vaporizer.

46. The drug assembly of claim 45, wherein the drug cartridge includes a tapered base.

47. The drug assembly of claim 46, wherein the tapered base has a 45 degree taper configured to improve thermal contact between the drug cartridge and the vaporizer and improve ease of detachment of the drug assembly from the vaporizer.83106261231.6Atty. Docket No. 119186-TBD48. The drug assembly of claim 34, wherein the drug in the drug cartridge has a dose of about 1 mg to about 25 mg or about 0.5 mg to about 100 mg.

49. The drug assembly of claim 34, wherein a bottom surface of the drug cartridge is recessed within the housing.

50. The drug assembly of claim 34, wherein the safety cover is coupled to the housing such that when the holding chamber is coupled to the housing, the holding chamber provides a force to the safety cover to uncouple the safety cover from the housing.51 . A mouthpiece comprising: a body; and a plurality of engagement features extending from the body, wherein each of the plurality of engagement features includes a locking portion operable to engage with a corresponding projection of a receiving portion of a holding chamber; wherein the body forms a lumen operable to be in fluid communication with an aerosol containment portion of the holding chamber; wherein the body forms a plurality of atmospheric channels in communication with ambient air.

52. The mouthpiece of claim 51 , further comprising: an interior projection configured to contact a linkage arm of the holding chamber.

53. The mouthpiece of claim 52, wherein the interior projection surrounds the lumen annularly.

54. The mouthpiece of claim 51 , wherein the plurality of atmospheric channels numbers four and two of the four atmospheric channels are on an opposite side of the lumen from another two of the four atmospheric channels.

55. The mouthpiece of claim 51 , wherein the mouthpiece includes a lip.84106261231.6Atty. Docket No. 119186-TBD56. The mouthpiece of claim 55, wherein the lip has an oval cross section.

57. The mouthpiece of claim 56, wherein the oval cross section has a minor diameter of about 10 mm to about 20 mm.

58. The mouthpiece of claim 57, wherein the oval cross section has a major diameter of about 30 mm to about 50 mm.

59. A holding chamber comprising: a receiving portion, which forms a lumen; an aerosol containment portion coupled to the receiving portion and in fluid communication with the lumen; a plurality of projections operable to couple to one or more engagement features of a mouthpiece; and a valve operable to have an open state and closed state, wherein the open state allows aerosol in the aerosol containment portion to flow through the lumen; wherein the valve is in a normally closed state, wherein the valve is operable to be in an open position when the mouthpiece is translated towards the receiving portion and / or when a drug assembly is coupled to the holding chamber.

60. The holding chamber of claim 59, wherein the aerosol containment portion is operable to contain an aerosolized drug.61 . The holding chamber of claim 59, wherein the receiving portion forms a plurality of finger grips.

62. The holding chamber of claim 61 , wherein each of the plurality of projections extend from a respective one of the plurality of finger grips.85106261231.6Atty. Docket No. 119186-TBD63. The holding chamber of claim 62, further comprising a linkage arm operable to be in contact with an interior projection of the mouthpiece or one or more posts of a drug assembly housing.

64. The holding chamber of claim 63, wherein the interior projection is operable to contact the linkage arm upon movement of the mouthpiece in a direction towards the receiving portion.

65. The holding chamber of claim 63, wherein the one or more posts are operable to contact the linkage arm upon coupling of the holding chamber to the drug assembly housing.

66. A vaporizer comprising: a drug assembly attachment port comprising an attachment mechanism operable to couple to a drug assembly; and a heating column operable to provide convective and conductive heating to the drug assembly; and wherein the drug assembly attachment port comprises two or more openings extending to a groove, the two or more openings each operable to receive a tab of two or more tabs of the drug assembly, wherein the groove is operable to receive the two or more tabs of the drug assembly and wherein the groove further includes two recesses, each recess operable to receive and lock a respective tab of the two or more tabs in place within the drug assembly attachment port.

67. The vaporizer of claim 66, further comprising a temperature sensor operable to measure a temperature of the heating column.

68. The vaporizer of claim 67, wherein the temperature sensor is operable to measure a temperature drop when the drug assembly is coupled to the drug assembly attachment port.86106261231.6Atty. Docket No. 119186-TBD69. The vaporizer of claim 66, wherein the heating column includes an upper tapered edge.

70. The vaporizer of claim 69, wherein the drug assembly includes a drug cartridge operable to hold a drug.

71. The vaporizer of claim 70, wherein the drug cartridge includes a bottom tapered edge configured to interface with the upper tapered edge of the heating column.

72. A method for coupling and / or operation of a mouthpiece in relation to a holding chamber containing an aerosolized drug, the method comprising: engaging a portion of the mouthpiece over a receiving portion of the holding chamber; rotating the mouthpiece such that two or more engagement features engage with a respective one of two or more finger grips of the holding chamber, thereby locking the mouthpiece in an installed configuration; and instructing a patient to press the mouthpiece in a direction towards the holding chamber, thereby opening a lumen formed in the holding chamber for inhalation of the aerosolized drug therethrough.

73. The method of claim 72, the method further comprising instructing the patient to continue inhalation through a plurality of atmospheric channels of the mouthpiece.

74. The method of claim 73, wherein the continued inhalation occurs after the aerosolized drug is completely evacuated from the holding chamber.

75. The method of claim 72, the method further comprising instructing the patient to discontinue the pressing on the mouthpiece, thereby moving a valve in communication with the lumen to an inactivated position and sealing the lumen.87106261231.6Atty. Docket No. 119186-TBD76. The method of claim 75, further comprising prior to the patient discontinuing the pressing, observing, via one or more indicators, that the aerosolized drug is completely evacuated from the holding chamber.

77. The method of claim 76, wherein the one or more indicators include visual indicators.

78. The method of claim 72, further comprising palpating the holding chamber to ensure that the aerosolized drug is completely evacuated.88106261231.6

Images